The Digital International Liver Congress™ 2021


23-26 June 2021 Virtual Conference
N. Poster
Poster title
Applicant name
  PO-019 Modeling Disease Burden of Nonalcoholic Fatty Liver Disease (NAFLD) in Japan Junko Tanaka Received Received
  PO-33 Association between sarcopenic obesity and nonalcoholic fatty liver disease and fibrosis detected by fibroscan Karn Wijarnpreecha Received Received
  PO-043 Preliminary pharmacokinetics and safety in healthy volunteers of VIR-3434, a monoclonal antibody for the treatment of chronic hepatitis B infection Wendy Re Received Received
  PO-048 Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode Ares Villagrasa Received Received
  PO-051 Aiming for HCV elimination - Optimizing DAA therapy by characterisation of patients lost to follow up (LTFU) in a large real world setting - Data from the German Hepatitis C-Registry (DHC-R) Yvonne Serfert Received Received
  PO-052 Persistent long-term risk of liver related complications in hepatitis C virus patients after antiviral therapy - Data from the German Hepatitis C-Registry (DHC-R) Yvonne Serfert Received Received
  PO-060 Quantification of polyreactive immunoglobulin G facilitates diagnosis of autoimmune hepatitis Bastian Engel Received Received
  PO-068 Prospective independent confirmation of guideline defined hepatitis C screening strategies within the Check-Up examination in the primary care setting Johannes Wiegand Received Received
  PO-75 Irreversible electroporation vs radiofrequency ablation for hepatocellular carcinoma: A single centre propensity matched comparison Elliot Freeman Received Received
  PO-080 End-of-treatment HBsAg, HBcrAg and HBV RNA levels predict sustained response and HBsAg loss in chronic hepatitis B patients Sylvia Brakenhoff Received Received
  PO-081 Economic consequences of anti-HCV treatment of patients diagnosed through screening in Italy: a prospective modeling analysis. Claudia Simonelli Received Received
  PO-089 Survivin inhibition ameliorates liver fibrosis via inducing senescence in hepatic stellate cells Sachin Sharma Received Received
  PO-094 Automated quantitation of histological features could predict mortality in patients with severe alcoholic hepatitis Luke Tyson Received Received
  PO-106 Social outcomes in patients with biliary atresia: a systematic review Emma Alexander Received Received
  PO-111 One-year safety results of the Nuc-Stop Study, an open-label study on stopping antiviral therapy in HBeAg negative chronic hepatitis B Asgeir Johannessen Received Received
  PO-117 Sulfated Steroids and Bile Acids and Dopamine Metabolites are Associated with Favorable Outcomes after Fecal Transplant in Alcohol Use Disorder Jasmohan Bajaj Received Received
  PO-127 Quality of life is impaired in both physical and mental health domains in patients with Autoimmune Hepatitis (AIH): A systematic review and meta-analysis of Patient-Reported Outcome Measures (PROMs) Selena Dixon Received Received
  PO-131 From screening to therapy: Anti-HCV screening and linkage to care in a network of general practitioners and a private gastroenterology practice Johannes Wiegand Received Received
  PO-133 Repression of fatty acid oxidation in steatohepatitic-HCC is mediated by E2F1 and E2F2 transcription factors Francisco Gonzalez-Romero Received Received
  PO-134 Genetic variation in the mitochondrial glycerol-3-phosphate acyltransferase is associated with liver injury Aaron Hakim Received Received
  PO-147 Hepatitis B vaccine NON-RESPONDERS show higher frequencies of REGULATORY B CELLS, but lower levels of IL-10 expression compared to responders Laureen Pohl Received Received
  PO-153 Prevalence and origin of rare HCV Genotypes in DAA-naive and DAA-experienced patients Julia Dietz Received Received
  PO-159 Target engagement and evidence of efficacy with PXL770, a novel direct AMP-Kinase activator, in a 4-week PK/PD trial in patients with NAFLD Vlad Ratziu Received Received
  PO-167 Derivation and validation of the NAFLD cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis and to predict liver-related outcomes Christian Labenz Received Received
  PO-175 A cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral target Gatan Ligat Received Received
  PO-186 Real-world experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant Pil Soo Sung Received Received
  PO-187 Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus Ellen Driever Received Received
  PO-190 Patients with LIVER CIRRHOSIS - SATISFACTION in a NURSE-LED outpatient clinic Marie Louise S. Hamberg Received Received
  PO-195 Role of Mcpip1 in obesity-induced hepatic steatosis as determined by myeloid and liver-specific conditional knockouts Natalia Pydyn Received Received
  PO-196 Chronic liver damage favours induction of CD44v6 epithelial cells and subsequent liver carcinoma formation Akshaya Srikanth Received Received
  PO-205 A new prediction equation for estimating body weight in cirrhotic patients with refractory ascites Bruna Alves Received Received
  PO-210 A Dose-Finding, Positive Proof of Concept study of HTD1801 in Patients with Primary Sclerosing Cholangitis Kris Kowdley Received Received
  PO-212 Early Renal Dysfunction Post Liver Transplant Predicts Long-term Adjudicated Cardiovascular Events Ramzi Hassouneh Received Received
  PO-216 Liver resident Natural Killer cells are the dominant source of Fas ligand during chronic Hepatitis B virus mediated liver damage Adrian Kuipery Received Received
  PO-218 Incidence and resolution of steatohepatitis in patients receiving entecavir for chronic hepatitis B Yiwen Shi Received Received
  PO-223 Precision-cut liver slices as a dynamic tool to model liver fibrosis in vitro Liza Dewyse Received Received
  PO-230 Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial Sven Francque Received Received
  PO-231 Effect of subcutaneous semaglutide on quality-of-life in patients with non-alcoholic steatohepatitis Manuel Romero-Gómez Received Received
  PO-235 Combined PD-1 blockade plus IL-15 treatment restores HBV-specific CD8 T cell reactivity in short-term nucleos(t)ide analogue treated eAg chronic hepatitis B Julia Peña Asensio Received Received
  PO-240 Identification of a CD8 T cell population with a transcriptional profile consistent with non-specific hepatocyte killing in the inflamed human liver of chronic hepatitis B patients Shirin Nkongolo Received Received
  PO-246 CD44v6gp38 large extracellular vesicles in gall bladder survival prognosis - a pilot study Bingduo Wang Received Received
  PO-247 On-treatment HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg negative patients Teresa Broquetas Received Received
  PO-250 prognostic value of a nomogram predicting microvascular invasion for patients with hepatocelluar carcinoma Liying Ren Received Received
  PO-251 Definition of healthy ranges for alanine aminotransferase levels: a 2020 update serena pelusi Received Received
  PO-254 Effectiveness of obeticholic acid in patients with primary biliary cholangitis stratified by biochemical marker status in the real-world setting in the United States Amy Law Received Received
  PO-258 Helicases DDX5 and DDX17 regulate hepatitis B virus transcriptional fidelity and RNA processing in infected human primary hepatocytes Guillaume GIRAUD Received Received
  PO-260 Risk factors for chronic hepatitis B among 0.5 million Chinese adults Elizabeth Hamilton Received Received
  PO-262 Blood-derived extracellular vesicles of patients with liver cirrhosis and acute-on-chronic liver failure display immunomodulatory functions Mona-May Langer Received Received
  PO-266 Liver volume measurement predicts development of hepatic encephalopathy in chronic hepatitis b patients Changhyun Lee Received Received
  PO-279 Ablation of liver FXR results in an increased colonic mucus barrier in mice Saskia van Mil Received Received
  PO-283 Transcriptomics identifies longitudinal biomarker gene signatures of NASH fibrosis regressors Christina Ebert Received Received
  PO-299 Clinical and radiological characterisation of Polycystic Liver Disease Benjamin Giles Received Received
  PO-301 Artificial Intelligence in medical imaging of the liver - a solution for Computed Tomography exam phases recognition João Martins Cortez Filho Received Received
  PO-302 Pharmacokinetics, Pharmacodynamics, and toxicology of SZN-043, a hepatocyte-targeted Wnt potentiator, in nonhuman primates Jay Tibbitts Received Received
  PO-309 Systemic inflammation promotes liver fibrogenesis and matrix turnover in patients with advanced chronic liver disease Benedikt Simbrunner Received Received
  PO-310 Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen Ida Villesen Received Received
  PO-313 The prognosis is impaired in NAFLD patients with diabetes despite negative FIB4 1.30 Jerome Boursier Received Received
  PO-323 Liver phenotype of adults with alpha-1 antitrypsin deficiency in the UK Biobank and in an international, multi-center cohort Malin Fromme Received Received
  PO-336 Differential requirement of RAS-dependent signaling pathways in tumor development and differentiation in murine liver cancer Carina Rupp Received Received
  PO-337 Funded referral to a commercial weight loss provider is effective in achieving weight loss in Non-alcoholic fatty liver disease Iain Hay Received Received
  PO-342 Improved survival and reduced risk of hospital admissions after 12-weeks of resistance training in patients with cirrhosis - a three year follow-up from randomization Luise Aamann Received Received
  PO-344 Immnohistochemical staining of cholangioscopy-directed biopsies of cholangiocarcinoma in Primary Sclerosing Cholangitis Stephanie Yan Received Received
  PO-345 Alcoholic foamy degeneration: a singular clinical entity that mimics alcoholic hepatitis and may be distinguished by serum triglyceride levels Jordi Gratacós-Ginès Received Received
  PO-351 Liver transplantation for NAFLD cirrhosis : early overall patient survival is good Franois Villeret Received Received
  PO-353 Disease recurrence after liver transplantation for NAFLD cirrhosis : just wait Franois Villeret Received Received
  PO-364 Waitlist outcomes for alcoholic hepatitis are more favorable than for other candidates with high Model for End-stage Liver Disease score in the current era Therese Bittermann Received Received
  PO-375 A profibrotic role for the orphan G-protein coupled receptor 176 during hepatic stellate cell activation Vincent De Smet Received Received
  PO-376 Machine learning in primary biliary cholangitis: a novel approach for risk stratification Alessio Gerussi Received Received
  PO-377 Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients Frank Tacke Received Received
  PO-381 relevance of psychosocial biomarkers on therapeutic adherence in patients with non-alcoholic fatty liver disease Jesús Funuyet-Salas Received Received
  PO-388 Increased screening, tailored access, linkage to care and treatment for PWUD through a patient centered program Alessandra Mangia Received Received
  PO-393 MET642, an FXR agonist with a unique chemotype, demonstrates a safe, sustained profile in a14-day randomized study in healthy subjects Richard Pencek Received Received
  PO-397 Novel hepatitis B virus gene expression inhibitor in clinical development Vadim Bichko Received Received
  PO-404 12 weeks treatment of Sofosbuvir/Velpatasvir in HCV negative recipients receiving renal transplantation from HCV positive donors Ruoyang Chen Received Received
  PO-408 Circulating HBV RNA correlates with intrahepatic covalently closed circular DNA (cccDNA) transcriptional activity in untreated and NUC-treated chronic hepatitis B (CHB) patients Barbara Testoni Received Received
  PO-409 Cause of Death and Cause-Specific Mortality in Primary Liver Cancer: Temporal Trends in a Hepatitis B Virus Endemic Area Bo Hyun Kim Received Received
  PO-410 The inhibition of the YAP-1/CTGF pathway improves chronic biliary fibrosis in the Abcb4-/- model by modulation of hepatic stellate cell physiology Liangtao Ye Received Received
  PO-418 Rifaximin and Fecal Microbiota Transplant beneficially modulate gut metagenomic virulence factors in cirrhosis: Analysis of two trials Jasmohan Bajaj Received Received
  PO-420 A 3-antigen prophylactic hepatitis B virus vaccine confers rapid onset of protection in young adults, age 18-45, compared to a single-antigen hepatitis B virus vaccine Francisco Diaz-Mitoma Received Received
  PO-424 Simplified test and treat protocols for population level screening and elimination of hepatitis B and hepatitis C in Uzbekistan Rick Dunn Received Received
  PO-425 Modelling the potential effectiveness of different screening and treatment strategies for hepatitis c during pregnancy in Ukraine Nadia Hachicha Maalej Received Received
  PO-430 High probability of reactive HBV-specific CD8 cells after stopping nucleos(t)ide analogue treatment forecast rapid HBsAg decrease in eAg(-) chronic hepatitis B Julia Peña Asensio Received Received
  PO-433 Drivers of outcome in compensated alcohol-related cirrhosis: a prospective study Alexandre Louvet Received Received
  PO-435 Hyperammoniemia and intrahepatic microcirculation disorders and its correction at the nonalcoholic steatohepatitis patients with initial stages of liver fibrosis Tatiana Ermolova Received Received
  PO-441 Low alcohol consumption is associated with a decreased frequency of cirrhosis and hepatocellular carcinoma in a cohort of NAFLD outpatients Bernardo Stefanini Received Received
  PO-442 SZN-043, a Hepatocyte-targeted-R-spondin mimetic, stimulates hepatocyte proliferation in an acute alcoholic hepatitis model Trevor Fisher Received Received
  PO-443 SZN-043, a hepatocyte targeted R-spondin mimetic, induces hepatocyte proliferation in acute acetaminophen-induced liver injury model Mehaben Patel Received Received
  PO-453 The impact of unrestricted access to direct-acting antiviral among 1001 incarcerated hepatitis C virus-infected patients Yu Jun Wong Received Received
  PO-454 Application of FIB-4 and NFS in primary care: Over 1/3 of older patients with diabetes meet criteria for high risk of advanced fibrosis with the use of age-specific cutoffs Kendall Islam Received Received
  PO-460 Persistent High HBsAg Levels Predict Lower Risk of Hepatocellular Carcinoma in HBeAg-seropositive Chronic Hepatitis B Patients Hsin-Che Lin Received Received
  PO-468 Direct antivirals can achieve a cure in all patients with chronic hepatitis C due to genotype 5. A French multicentre study. Carine Nicolas Received Received
  PO-469 Study of the effect of the hepatitis D virus on the hepatitis B virus quasispecies in mice models by a next-generation sequencing approach David Tabernero Received Received
  PO-470 Restoration of altered bile acid pool prevents the development of nonalcoholic steatohepatitis Justine Gillard Received Received
  PO-475 Inactivation of ACSL5, an interacting protein of TM6SF2, results in decreased plasma TG and cholesterol without affecting hepatic lipids Fei Luo Received Received
  PO-477 hepatic lpi/gpr55 systemregulates the development of non-alcoholic steatosis and steatohepatitis Uxía Fernández Received Received
  PO-479 Inhibition of hepatic p63 reduces the fibrosis in NASH Marcos F Fondevila Received Received
  PO-482 Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection Lisa Danzig Received Received
  PO-485 Baveno-VI criteria to predict variceal bleeding and liver decompensation in compensated cirrhosis patients FRANCIS TEH BAN Received Received
  PO-487 Binge drinking induces an acute release of markers of hepatic fibrogenesis (PRO-C3) Nikolaj Torp Received Received
  PO-488 Has the 5-year mortality of patients with alcoholic cirrhosis changed during the last 20 years ? Edeline Kaze Received Received
  PO-504 Innovative linkage model to re-engage lost-to-follow-up individuals in the national hepatitis C elimination program of Georgia Amiran Gamkrelidze Received Received
  PO-511 Health status perception and patient experience in liver cancer patients participating in Nurse-led Educational Programs Neus Llarch Alfonso Received Received
  PO-525 Pooling plasma samples for hepatitis C RNA detection: a strategy to expand access to diagnostics Federico Garcia Received Received
  PO-526 Real life kinetics of new HBV markers during treatment of chronic hepatitis D with bulevirtide CHARLOTTE PRONIER Received Received
  PO-529 Clinical importance of a new, high-sensitivity HBcrAg assay for monitoring chronic hepatitis B and HBV reactivation Takako Inoue Received Received
  PO-530 Chances of renal recovery in liver only transplant recipients who were eligible for simultaneous liver-kidney transplant Jiawei Cui Received Received
  PO-532 Clinical outcomes of cirrhotic patients with dysregulated hormones of vascular homeostasis Lukas Hartl Received Received
  PO-533 Healthcare restrictions due to COVID-19 impaired liver care, lowered patient satisfaction and increased liver-related mortality Lukas Hartl Received Received
  PO-534 Pharmacokinetics of tropifexor, a potent farnesoid X receptor agonist, are similar in subjects with mild, moderate, and severe hepatic impairment: results from a multicentre, open-label, single-dose study Rowan Stringer Received Received
  PO-537 Protective effect of GOLM1 on acute liver failure in mice Linlan Qiao Received Received
  PO-539 Promoting Hepatitis Virus Screening Test at Worksite in Japan Using Nudge Theory compared with Full Subsidies Masaaki Korenaga Received Received
  PO-541 Molecular characterization of HCC in Mongolia delineates unique genomic features Laura Torrens Received Received
  PO-550 serpina3c deficiency promotes high-fat diet-induced steatohepatitis through mediating necroptosis via -catenin-foxo1 axis linglin qian Received Received
  PO-552 The landscape of mitochondrial dysfunction in circulating leukocytes of patients with acute-on-chronic liver failure is characterized by altered mitochondrial metabolism and structure Ingrid Zhang Received Received
  PO-560 Decreasing VWF levels upon NSBB therapy indicate a reduced risk of further decompensation, ACLF and death Mathias Jachs Received Received
  PO-561 Recent portal venous system thrombosis associated with Cytomegalovirus disease: results of a multicenter study Chloé De Broucker Received Received
  PO-565 A prospective cohort study for the prevalence and screening policy of NAFLD in patients with T2DM in primary care Roberta Forlano Received Received
  PO-566 Association between hepatic fat and subclinical vascular disease burden in the general population Xinting Cai Received Received
  PO-567 B-cell-mediated fibrogenesis in non-alcoholic steatohepatitis Anja Moncsek Received Received
  PO-569 long term prognosis of patients with alcoholic disease or nafld according to metabolic syndrome or alcohol use Marie DECRAECKER Received Received
  PO-570 Portal vein recanalization for severe portal hypertension related to chronic non-cirrhotic extrahepatic portal vein obstruction: long term results Florent Artru Received Received
  PO-573 TIAM1, a potential synthetic lethal gene and candidate therapeutic target for hepatocellular carcinoma Chalermsin Permtermsin Received Received
  PO-574 Pre-transplant AFP 25.5 is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria Bianca Magro Received Received
  PO-578 Long-term follow up in patients with hepatitis C virus treated with direct-acting-ativirals agents Paula Fernández Alvarez Received Received
  PO-580 Modeling regional variation in the return on investment of VCTE for fatty liver disease (FLD) in the U.S. Mazen Noureddin Received Received
  PO-591 Higher number of transarterial treatments might have detrimental effects on the overall survival of patients eventually receiving systemic treatments Vito Sansone Received Received
  PO-594 Incidental Cholangiocarcinoma in Liver Transplantation Nawaz Safdar Received Received
  PO-602 Persistent perturbation of the circadian clock by chronic hepatitis C virus infection following cure with direct-acting antivirals Frank Jhling Received Received
  PO-607 Acamprosate for the treatment of alcohol use disorder may be safer than baclofen in patients with cirrhosis Luke Tyson Received Received
  PO-608 Multicellular primary mouse liver spheroids for DILI, NAFLD, NASH and fibrosis studies Elise Anne van Os Received Received
  PO-611 Adaptation of hepatitis C virus to efficient infection of mouse hepatocytes Julie Sheldon Received Received
  PO-614 Additive Effects of Diabetes and NAFLD on Liver Disease Severity and Clinical Outcomes in the General Population (NASH-CO Study) Oumarou NABI Received Received
  PO-624 Transcriptomic profiling of liver sinusoidal endothelial cells during cirrhosis progression reveals stage-specific secretory signature Jordi Gracia-Sancho Received Received
  PO-626 assembly dynamics and infection efficacy of hepatitis b virus surface protein exchanges in the eight hepatitis d virus genotypes Wenshi Wang Received Received
  PO-627 Hepatic magnesium accumulation upon cyclin M4 (CNNM4) silencing improves NASH Jorge Simón Received Received
  PO-629 Multiparametric MRI as non-invasive tool to assess disease activity in autoimmune hepatitis johannes hartl Received Received
  PO-630 Undiagnosed obstructive sleep apnoea is a major component in NAFLD quality of life impairment Wenhao Li Received Received
  PO-632 Prevalence of hepatic steatosis and advanced fibrosis in patients living with HIV in Germany Maurice Michel Received Received
  PO-637 Achieving hepatitis C micro-elimination in prisons through High Intensive Test and Treat (HITT) interventions Sean Cox Received Received
  PO-640 Using the copula method to accurately estimate the impact of body mass index and alcohol consumption on liver disease Lise RETAT Received Received
  PO-649 Impact of extending DAAs availability in France: a five-year overview (2015-2019) of data from French administrative healthcare databases (SNDS) Elias Benabadji Received Received
  PO-655 Depletion of T cells via inducible caspase 9 increases safety of adoptive T-cell therapy against chronic hepatitis B Alexandre Klopp Received Received
  PO-663 Pharmacokinetics, safety, and tolerability of multiple-dose CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in healthy Japanese and non-Japanese adults Ying Ye Received Received
  PO-665 Transcriptomic analyses reveal variation of liver inflammation across phases of chronic hepatitis B infection Ricardo Ramirez Received Received
  PO-666 Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed After HCV SVR MING-LUN YEH Received Received
  PO-668 Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects Jaymin Shah Received Received
  PO-675 Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure Florence Wong Received Received
  PO-676 An episode of detectable serum hepatitis B virus-DNA level does not affect risk of hepatic decompensation among untreated compensated cirrhosis patient with viral load of 2,000 IU/mL Hye Won lee Received Received
  PO-677 New mouse model of cholangiocarcinoma arising in the setting of progressive biliary injury and fibrosis Pinzhu Huang Received Received
  PO-679 Development and validation of a noninvasive algorithm to predict significant fibrosis in patients with chronic drug-induced liver injury Dong Ji Received Received
  PO-685 The benefits of the novel nomenclature of metabolic fatty liver disease Álvaro Santos-Laso Received Received
  PO-689 Titer and breadth of anti-hepatitis C virus E2-glycoprotein antibodies in cirrhotic patients after direct antiviral agent therapy Daniel Sepúlveda-crespo Received Received
  PO-690 depist C pharma, an innovative outreach HCV screening project in pharmacy for drug users and general population Andre-Jean Remy Received Received
  PO-692 HBV induces collagen VI expression by hepatocytes promoting liver fibrosis Alessia Virzi Received Received
  PO-697 Incidence of liver and non-liver related events and mortality in a large cohort of HCV cirrhotics with an SVR to DAA: a 5-year single center study Roberta DAmbrosio Received Received
  PO-698 Characterizing sensory thresholds and autonomic dysfunction in cirrhotic patients with minimal hepatic encephalopathy Dalia Rega Received Received
  PO-700 Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity Christophe Ramière Received Received
  PO-707 Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study Linda Skibsted Kornerup Received Received
  PO-709 Multi-omic analysis unveils biological pathways in peripheral immune system associated to minimal hepatic encephalopathy appearance in cirrhotic patients Carmina Montoliu Received Received
  PO-711 Binge Eating Disorder is associated with an unfavourable body mass composition in patients with Non-Alcoholic fatty liver disease Roberta Forlano Received Received
  PO-712 fibrinogen-like protein 2 promotes fulminant hepatitis by inducing neutrophil activition and neutrophil extracellular traps formation jinshang Hu Received Received
  PO-714 prognostic impacts of the change in muscle mass on patients with cirrhosis Tae Hyung Kim Received Received
  PO-715 One-year safety and efficacy of tenofovir alafenamide (TAF) in chronic hepatitis B (CHB): a HEllenic multicenter ReAl-life CLInical Study (HERACLIS TAF) George Papatheodoridis Received Received
  PO-716 distinctive alterations of the hepatic unfolded protein response in models of diabetes and non-alcoholic fatty liver disease Bedair Dewidar Received Received
  PO-717 Non-invasive tests to predict liver-related events in a single-center cohort of 486 HCV cirrhotic patients treated with DAA Elisabetta Degasperi Received Received
  PO-718 Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy Sam Murray Received Received
  PO-719 Carriage of CYP2E1rs2070673:A is associated with higher prevalence of nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease Hong-Lei Ma Received Received
  PO-725 Effects of empagliflozin and L-ornithine L-aspartate on behaviour, cognitive function, and physical performance in mice with non-alcoholic steatohepatitis Veronika Prikhodko Received Received
  PO-733 Pharmacokinetics, safety, and tolerability of CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in participants with hepatic impairment Kofi Mensah Received Received
  PO-737 Genetic haemochromatosis, a common disorder but are General Practitioners still unaware? A qualitative study Geraldine (Gerri) Mortimore Received Received
  PO-739 Micro-elimination of Hepatitis C in prisons of Punjab, India Kanudeep Kaur Received Received
  PO-745 Simulations of HCV vaccine trials reveal opportunities to re-evaluate vaccine efficacy Harel Dahari Received Received
  PO-750 Two trans-arterial chemo-embolizations during liver transplantation waiting list and absence of complete radiological response: time for a systemic strategy? Edoardo Poli Received Received
  PO-751 M comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography Valentin Blank Received Received
  PO-756 Combination treatments including semaglutide, cilofexor, and/or firsocostat lead to greater improvements in the FibroScan-AST (FAST) score compared with semaglutide alone in patients with non-alcoholic steatohepatitis Naim Alkhouri Received Received
  PO-757 Fenofibrate is safe and mitigates increases in serum triglycerides in NASH patients treated with the combination of the ACC inhibitor firsocostat and the FXR agonist cilofexor: A randomized trial Eric Lawitz Received Received
  PO-767 Comparison of HBV-related HCC Incidence Between Entecavir and Tenofovir Treated Cohorts: A Population-based Study Sichan He Received Received
  PO-769 A novel radiomics signature based on T2WI accurately predicts hepatic inflammation in individuals with biopsy-proven NAFLD: a derivation and independent validation study Zhong-Wei Chen Received Received
  PO-770 Real-world evaluation of second line therapy in Primary Biliary Cholangitis: A multicentre nationwide study Nadir Abbas Received Received
  PO-773 Frequency and impact of potential multiple drug-drug interactions (DDIs) associated with pangenotypic direct-acting antivirals in patients receiving opioid substitution therapy Frank Tacke Received Received
  PO-774 A combination of gapmers and/or siRNA as potential gene therapy strategy against HBV infection: in vitro results. Maria Francesca Cortese Received Received
  PO-775 The effectiveness of a community based two-tier risk stratification pathway for non-alcoholic fatty liver disease Rebecca Harris Received Received
  PO-778 The FXR-RXR interaction inhibits FXR isoform-specific gene activation in liver cells Jose Miguel Ramos Pittol Received Received
  PO-785 RECONVOCC : Can we reconvene chronic hepatitis C patients who were lost to follow-up ? Frederic Faure Received Received
  PO-787 Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical models of fibrosis Jung Kuk Kim Received Received
  PO-793 Endothelial GATA4 deficiency causes perisinusoidal liver fibrosis by impaired angiocrine signaling Manuel Winkler Received Received
  PO-797 Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: A multi-center,prospective clinical study Guorong Han Received Received
  PO-799 Response failure to ursodeoxycholic acid treatment in primary biliary cholangitis is associated with a distinct stool and urine secondary bile acid profile Laura Martinez-Gili Received Received
  PO-811 Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B Dong Ji Received Received
  PO-813 Prognosis of severe HBV reactivation in Western countries: role of the MELD score Edoardo Poli Received Received
  PO-815 Efficacy and safety of 8- or 12 weeks of glecaprevir/pibrentasvir in patients with signs of portal hypertension Robert Brown Received Received
  PO-818 Transient splenic elastography predicts high-risk esophageal varices in patients with noncirrhotic portal hypertension Joel Ferreira-Silva Received Received
  PO-819 Real-world assessment of NAFLD stages using FibroScan in the US population and diabetes subpopulation based on data from NHANES 2017-2018 Mazen Noureddin Received Received
  PO-820 Viral factors and host response in chronic HDV infection Ester Garcia-Pras Received Received
  PO-821 Usefulness of FIB-4 as a screening test for chronic liver disease in a university hospital Victor de Ledinghen Received Received
  PO-824 Preliminary On-Treatment Data From a Phase 2 Study Evaluating VIR-2218 in Combination With Pegylated InterferonAlfa-2a in Patients With Chronic Hepatitis B Infection Wendy Re Received Received
  PO-825 Use of machine learning to develop a NAFLD screening tool using demographic, clinical and FibroScan data from the NHANES 2017-2018 database Birol Emir Received Received
  PO-831 Liver related and extrahepatic events in patients with nonalcoholic fatty liver disease: a competing risk analysis Grazia Pennisi Received Received
  PO-832 Prevalence of steatosis and fibrosis in individuals with high-alcohol consumption assessed by FibroScan: real-world cohort study from the US population Naim Alkhouri Received Received
  PO-835 Safety of 11,043 paracentesis in patients with liver cirrhosis with and without anticoagulant treatment. Large, retrospective, unicentric study. Jordi Vives Moreno Received Received
  PO-836 Patients with elevated Fibrosis-4 Index or NAFLD Fibrosis Score have higher rates of cardiovascular events: a post-hoc analysis from two large, randomised statin clinical trials in 18 814 patients Frank Tacke Received Received
  PO-838 Combination of an acetyl-CoA carboxylase inhibitor and fibroblast growth factor 19 reduced tissue triglyceride content and fibrosis in human precision-cut liver slices WEN-WEI TSAI Received Received
  PO-841 Elevated donor-derived cell-free DNA during subclinical T-cell mediated rejection after liver transplantation Anna Katharina Baumann Received Received
  PO-846 Chronic Hepatitis B inflammation gives rise to a novel macrophage population in the human liver Juan Diego Sanchez Received Received
  PO-851 Study on multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH Jung Kuk Kim Received Received
  PO-852 Identification of novel host factors in the patho-biology of Hepatitis B Virus (HBV) infection Collins Oduor Owino Received Received
  PO-853 A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B Renae Walsh Received Received
  PO-855 Potential effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical model of cholestatic liver disease Jung Kuk Kim Received Received
  PO-857 Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma Won-Mook Choi Received Received
  PO-860 Hepatolithiasis is a frequent and prognostic finding in patients with primary sclerosing cholangitis Bellal Jubran Received Received
  PO-861 Exploring host liver responses to Hepatitis B Virus at single cell resolution Balakrishnan Chakrapani Narmada Received Received
  PO-862 Mortality risk following HCV cure among people with HIV coinfection Naveed Janjua Received Received
  PO-864 Further analysis of simvastatin safety trial in patients with decompensated cirrhosis provides promising information about improving liver function and reducing cirrhosis severity Alberto Muñoz Received Received
  PO-866 Comparing traditional machine learning and deep learning models to Fibrosis-4 index in the prediction of non-alcoholic fatty liver disease-associated liver fibrosis Devon Y. Chang Received Received
  PO-872 Circulating B-cell activating factor of the tumour necrosis family (BAFF) and interleukin 21 levels predict treatment response in patients with autoimmune hepatitis Maaike Biewenga Received Received
  PO-881 Gender differences in microRNAs profile in HIV patients after HCV eradication with DAAs: potential biased consequences Daniel Valle Millares Received Received
  PO-889 Digital pathology with artificial intelligence analyses reveal new dynamics of treatment-induced fibrosis regression in nonalcoholic steatohepatitis Nikolai Naoumov Received Received
  PO-891 An innovative treatment for Primary Hyperoxaluria Type 1 based on specific gene correction and hepatic direct cell reprogramming Virginia Nieto-Romero Received Received
  PO-895 cell cycle-regulatory genetic aberrations and their prognostic implications in early-stage hepatocellular carcinomas Jihyun An Received Received
  PO-896 Stimulation of Mucosal-associated invariant T (MAIT) cells by human serum derived from peripheral and portal blood Martin LETT Received Received
  PO-899 Deletion of Mcpip1 in Mcpip1fl/flAlbCre mice recapitulates the phenotype of human primary biliary cholangitis Jerzy Kotlinowski Received Received
  PO-903 cholangiopathy-related necroptotic cell death recapitulated in human cholangiocyte organoids for screening novel drug targets Shaojun Shi Received Received
  PO-908 diagnostic accuracy of dried blood spot and plasma separation card samples for testing hepatitis c virus rna Agnes Malobela Received Received
  PO-915 METABOLIC dysfunction associated FATTY LIVER disease and adverse clinical outcomes in patients with CHRONIC HEPATITIS B Laurens Van Kleef Received Received
  PO-916 Nonalcoholic fatty liver disease cardiovascular risk by metabolic subtype David Fernández Received Received
  PO-918 Low myocardial mechano-energetic efficiency is an independent predictor of prognosis in patients with advanced chronic liver disease Maurizio Cesari Received Received
  PO-919 Comparative diagnostic accuracy of blood-based biomarkers for diagnosing NASH: phase 1 results of the LITMUS project Yasaman Vali Received Received
  PO-920 immuno-responsive classification of hepatocellular carcinomas as a potential surrogate for precision immuno-oncology Jihyun An Received Received
  PO-921 PIVKA-II levels predict hepatocellular carcinoma development in caucasian HCV cirrhotic patients treated with DAAs Elisabetta Degasperi Received Received
  PO-922 a novel score to risk stratify and optimize use of liver graft among patients with grade 3 acute on chronic liver failure ASHWANI SINGAL Received Received
  PO-932 Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according with the new proposed classification Maurizio Cesari Received Received
  PO-935 Liver transplantation for severe alcoholic hepatitis: a multicentre Italian study Giacomo Germani Received Received
  PO-938 Therapeutic targeting of integrin alpha v beta 1 in liver fibrosis Emma Shepherd Received Received
  PO-941 Independent validation of Agile 4: novel FibroScan based score for the diagnosis of cirrhosis in patients with non-alcoholic fatty liver disease Jerome Boursier Received Received
  PO-942 Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer Michael Vaine Received Received
  PO-944 Prognostic value of FibroScan based Agile 3 and Agile 4 scores in patients with non-alcoholic fatty liver disease Jerome Boursier Received Received
  PO-947 Immunogenetic diversity predicts viral control in chronic HBV (CHB) patients after discontinuation of direct antiviral treatment Tuefferd Marianne Received Received
  PO-950 A serum metabolic fingerprint may predict advanced fibrosis due to NAFLD in a cohort of diabetic patients Roberta Forlano Received Received
  PO-951 High rates of hidden HCV infections among hospitalized patients aged 55-85 Alessandra Mangia Received Received
  PO-955 Cost and effectiveness of treatment at Day 1 (Rapid Start) for hepatitis C and screening intensification in high-risk populations (T&T strategy) in France Elias Benabadji Received Received
  PO-968 Terlipressin improves renal replacement therapy-free survival in hepatorenal syndrome type 1 Juan Carlos Q. Velez Received Received
  PO-969 Successful implementation of a weight loss intervention pathway for non-alcoholic fatty liver disease patients by advanced practice hepatology providers with obesity training Vicki Shah Received Received
  PO-974 Evaluation of cardiac function in cirrhosis across different prognostic stages; A focus on plasma biomarkers of fibrosis Jolanta Zuwa&322;a-Jagie&322;&322;o Received Received
  PO-975 long-term effect of hcv eradication with direct acting antiviral (daas) therapy on egyptian patients with mixed cryglobulinemias(mc) Mohamed Elnadry Received Received
  PO-980 Incidence rates of hepatobiliary outcomes among patients with non-alcoholic steatohepatitis based on fibrosis-4 score severity at baseline Christine Coco Received Received
  PO-981 Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with nonalcoholic steatohepatitis Arun Sanyal Received Received
  PO-982 Development of a novel rat bioreactor to facilitate manufacture of human hepatocyte cell therapies for the treatment of patients with severe liver diseases Ray Hickey Received Received
  PO-983 Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination Kyle Hammond Received Received
  PO-984 Hepatopulmonary Syndrome is related with the Development of Acute-on Chronic Liver Failure and Poor prognosis in Cirrhotic patients. Han Seul Ki Received Received
  PO-985 The liver fibroinflammatory marker cT1 is reduced with aldafermin therapy in a randomized, double-blind, placebo-controlled, multicenter study in patients with nonalcoholic steatohepatitis Lei Ling Received Received
  PO-987 Alfosbuvir (SH229) plus daclatasvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 study Xian Zhang Received Received
  PO-990 Tenofovir Alafenamide Used Throughout Pregnancy in Chinese Active Chronic Hepatitis B Mothers: A Multicenter Prospective Study Qing-Lei Zeng Received Received
  PO-994 Hepatic fat loss in cirrhosis: Evaluation of malnutrition using MRI proton density fat fraction (MRI-PDFF) ATSUSHI NAKAMURA Received Received
  PO-1000 Association of Vitamin D receptors CdX-2 polymorphism and related haplotypes in patients with chronic hepatitis B infection in the inactive carrier and chronic hepatitis phases: a case-control study Prooksa Ananchuensook Received Received
  PO-1001 External Validation of the FAST Score as a Predictor of Fibrotic NASH in a Large Cohort of U.S. Adults with Biopsy-Proven NAFLD Prido Polanco Received Received
  PO-1004 safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis b Edward Gane Received Received
  PO-1007 A comprehensive HBsAg-positive patient centered screening strategy targeting microelimination of Hepatitis C virus in Chongqing,China DACHUAN CAI Received Received
  PO-1010 Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study. Lorena Carballo-Folgoso Received Received
  PO-1017 Non-invasive scores of hepatic fibrosis in autoimmune hepatitis Marco Ferronato Received Received
  PO-1020 Individualized polygenic risk score identifies NASH in the eastern Asia region: a derivation and validation study Feng Gao Received Received
  PO-1023 Intravital dynamic and correlative imaging reveals the mechanism of canalicular bile flux Nachiket Vartak Received Received
  PO-1026 Serum nuclear magnetic resonance metabolomic signature can discriminate between immunoglobulin G4-related sclerosing cholangitis and primary sclerosing cholangitis Emmanuel Selvaraj Received Received
  PO-1027 A low carbohydrate diet partially prevents the hepatic phenotype of hepatocyte OGT-deficient mice. Lucia Parlati Received Received
  PO-1029 Acute hepatitis C virus infection: A prospective ten years observational study of HCV-mono- and HCV/HIV-coinfected patients Christiana Graf Received Received
  PO-1030 Associations of Hydroxysteroid 17-Beta Dehydrogenase 13 Variants with Liver Histology In Chinese Patients with Metabolic-Associated Fatty Liver Disease Wen-Yue Liu Received Received
  PO-1032 Impact of hyponatremia on morbidity, mortality and resource utilization in portal hypertensive ascites: a nationwide analysis JOSEPH ALUKAL Received Received
  PO-1035 A novel approach to age cohort screening for hepatitis C in the primary care setting of a large urban health care setting with linkage to care David Bernstein Received Received
  PO-1037 Inhibition of ATG3 ameliorates liver steatosis and improves fatty acid metabolism Eva María Novoa Deaño Received Received
  PO-1038 A scoring model to predict mortality in hospitalized patients with decompensated cirrhosis and hyponatremia JOSEPH ALUKAL Received Received
  PO-1040 The natural history of advanced chronic liver disease defined by transient elastography Jessica Shearer Received Received
  PO-1045 A Double Blind, Randomised, Placebo-Controlled Study To Assess Safety and Tolerability of Oral Enterosorbent Yaq-001 In Cirrhotic Patients (CARBALIVE Consortium) Jane Macnaughtan Received Received
  PO-1047 Jaundice detection by deep convolutional neural network using smartphone images Tung-Hung Su Received Received
  PO-1051 Systemic and hepatic endothelial cell activation biomarkers expression are associated with inflammation and disease progression in patients with cirrhosis Jelte Schaapman Received Received
  PO-1056 Biomarker screening strategies to identify at-risk NASH cases for clinical trial recruitment in NAFLD Yasaman Vali Received Received
  PO-1064 Emergency room care is essential in improving outcomes of decompensated cirrhosis patients: A Canadian experience Abdel-Aziz Shaheen Received Received
  PO-1069 The AST/AST ratio: a second line component of the hepatic fibrosis screening by FIB-4 calculated automatically in 131,861 subjects. DENIS OUZAN Received Received
  PO-1074 The FGF19 analogue aldafermin enriches the lactate-consuming, bile acid-sensitive commensal microbe Veillonella in patients with primary sclerosing cholangitis Lei Ling Received Received
  PO-1082 Atherosclerotic cardiovascular risk assessment in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin Nadege T. Gunn Received Received
  PO-1090 The impacts of gender differences in muscle mass and adipose tissue on the outcomes of hepatocellular carcinoma after surgical resection Pei-Chang Lee Received Received
  PO-1091 CHESS criteria for screening and monitoring of varices needing treatment: an international multicenter study Chuan Liu Received Received
  PO-1094 Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): a nationwide cohort study Yifei Huang Received Received
  PO-1099 The alarming impact of COVID-19 pandemic on alcohol-related liver disease: a population-based Canadian study Abdel-Aziz Shaheen Received Received
  PO-1102 Epidemiology of spontaneous bacterial peritonitis and bacterascites in patients with cirrhosis in Queensland, Australia from 2008-2017 Amy Johnson Received Received
  PO-1103 In-hospital mortality after surgery in patients with liver cirrhosis: A nationwide study of 1,662,887 patients Jeong-Ju Yoo Received Received
  PO-1106 Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with NAFLD Yu-Jie Zhou Received Received
  PO-1107 Acute liver injury among patients with COVID-19 in a tertiary hospital Henry Winston Li Received Received
  PO-1112 Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 Study of FASN Inhibitor TVB-2640 MARIE OFARRELL Received Received
  PO-1115 Clinical aspect of coronavirus disease 2019 (COIVD-19) on HBV infected patients in term of Health Insurance Review & Assessment service data Young Kul Jung Received Received
  PO-1118 Metabolic reprogramming in a c-Myc/h-Ras transgenic mouse model of hepatocellular carcinoma Marina Serra Received Received
  PO-1119 Anti-apoptotic effect of mycophenolate mofetil in human hepatocytes cultures Razvan Iacob Received Received
  PO-1124 Hepatocellular carcinoma recurrence after direct-acting antiviral therapy for hepatitis C virus. A systematic review and meta-analysis. Leonardo Frazzoni Received Received
  PO-1125 Using the Enhanced Liver Fibrosis test in Primary Care: A practical pathway to prioritise patients with fibrosis in Fatty Liver Disease Alexander Hinkson Received Received
  PO-1126 Patients with MELD exceptions have higher access to liver transplantation and lower waiting list mortality: the Swiss nationwide experience Melisa Dirchwolf Received Received
  PO-1133 Post-transplant outcomes of previously refused liver grafts: a 10-years nationwide experience Chiara Becchetti Received Received
  PO-1142 Duration of response and outcomes in advanced hepatocelluar carcinoma patients with objective response to sorafenib: role of sub sequent treatment. Kuo-Wei Huang Received Received
  PO-1146 Metamizole intake is associated with acute kidney injury in patients with decompensated liver cirrhosis Tammo Tergast Received Received
  PO-1150 The hepatic IKK-NFkB axis induces liver steatosis by increasing de novo lipogenesis and cholesterol synthesis Andries Heida Received Received
  PO-1151 Stratifying the risk of variceal bleeding by non-invasive tools in patients with compensated advanced chronic liver disease: A decision curve analysis Sanchit Sharma Received Received
  PO-1152 Risk stratification based on liver stiffness and platelets for decompensation events in patients with compensated cirrhosis Ruiling He Received Received
  PO-1153 Weight variations and level of estrogen exposure predict the evolution of hepatocellular adenomas Alix Demory Received Received
  PO-1154 Influence of human fecal bacterias secretome in the maturation and function of the liver Joana I. Almeida Received Received
  PO-1158 Baseline characteristics of a large multi-site chronic HBV electronic health record-based cohort in the UK Cori Campbell Received Received
  PO-1161 Impact of INFECTIONS on the post-operative survival of ACUTE-ON-CHRONIC LIVER FAILURE patients undergoing LIVER TRANSPLANTATION Elina Lam Received Received
  PO-1164 External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population Hanne strm Received Received
  PO-1165 Cirrhocare - a pilot study of digital home-monitoring of advanced cirrhosis to determine feasibility and utility to diagnose new decompensation events. Konstantin Kazankov Received Received
  PO-1168 Graft survival following retransplantation - a large single centre retrospective analysis James Morgan Received Received
  PO-1169 Changes in the Profile and Outcomes of Paediatric Liver Transplantation in the United States Carey Escheik Received Received
  PO-1176 Hepatitis C virus eradication improves cognition in patients with and without cirrhosis: results from a real-life prospective study. Luis Ibáñez-Samaniego Received Received
  PO-1185 Magnesium homeostasis by Cyclin M4: a novel therapeutic mechanism in Acetaminophen-induced liver damage Irene Gonzalez Recio Received Received
  PO-1186 Detection of active hepatitis C by two-step point-of-care based strategy and linkage to care among excluded people using a mobile unit in Madrid, Spain. Pablo Ryan Received Received
  PO-1193 Lifestyle changes after cured Hepatitis C patients and adherence of a nurse-led liver cancer screening program Núria Granel Received Received
  PO-1195 PNPLA3 and SERPINA1 are associated with liver disease severity in an uned fatty liver disease cohort Lorenz Balcar Received Received
  PO-1196 ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model Jin Hong Received Received
  PO-1198 Efficacy Signals Of 4-Week Oral DUR-928 in NASH Subjects WeiQi Lin Received Received
  PO-1202 Curriculum-based education in NAFLD/NASH improves knowledge, competence, and confidence among gastroenterologists Shari Dermer Received Received
  PO-1205 Metabolic dysfunction-associated fatty liver disease (MAFLD) rather a bystander than a driver of mortality Georg Semmler Received Received
  PO-1207 Selective hypoxia-inducible-factor stabilisation alleviates hepatocellular steatosis and ballooning in a rodent model of 70 liver resection Samuele Iesari Received Received
  PO-1215 Cell specific roles of MLKL in alcohol-assoicated liver disease Xiaoqin Wu Received Received
  PO-1217 Hepatocellular carcinoma in patients with NASH is associated with a specific pattern of muscle fat infiltration: a first-order radiomics study based on MRI-PDFF Maxime Nachit Received Received
  PO-1220 PNPLA3 and TM6SF2 are neither associated with decreased cardiovascular nor increased liver-related mortality in the general population Lorenz Balcar Received Received
  PO-1221 Importance of a clinical pharmacist specialized in hepatitis C treatment for the management of potential drug-drug interactions in a multidisciplinary ECHO hepatitis C expert team Yaroslav Filippov Received Received
  PO-1222 PNPLA3-associated cirrhosis: HSD17B13 and MBOAT7 variants as modulators of chronic liver injury. Matthias Reichert Received Received
  PO-1227 Poor Awareness of Non Alcoholic Fatty Liver Disease (NAFLD) Among Adults in the United States Carey Escheik Received Received
  PO-1230 FIB-4 improves LSM-based prediction of clinical decompensation in overweight or obese patients with compensated advanced chronic liver disease Yuly Paulin Mendoza Received Received
  PO-1235 Proteomics Signature of Advanced Fibrosis in Non-alcoholic Steatohepatitis (NASH) using Data-independent Acquisition (DIA) Mass Spectrometry Carey Escheik Received Received
  PO-1236 Beta-blockers to prevent decompensation of cirrhosis: an emulation of the PREDESCI trial Elliot Tapper Received Received
  PO-1238 Natural history and clinical impact of non-neoplastic portal vein thrombosis in cirrhotics with hepatocellular carcinoma SARAH SHALABY Received Received
  PO-1240 Pharmacokinetics of ATI-2173, a novel active site polymerase inhibitor nucleotide (ASPIN), in a Phase 1b clinical trial Katherine Squires Received Received
  PO-1243 Direct oral anticoagulants (DOACs) for off-label use in patients with Budd Chiari Syndrome (BCS) Georg Semmler Received Received
  PO-1244 The prevalence of PSYCHIATRIC comorbidities in WILSONS DISEASE Merjem Begic Received Received
  PO-1247 New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: evaluation by CAP and LSM Annalisa Cespiati Received Received
  PO-1249 Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease Georg Semmler Received Received
  PO-1251 Phase 1 results for ATI-2173, a novel active site polymerase inhibitor nucleotide (ASPIN), in HBV-infected subjects Douglas Mayers Received Received
  PO-1257 Combination drug interactions of hepatitis B virus ( HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo Hua Tan Received Received
  PO-1263 Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma Thi Thu Nga Nguyen Received Received
  PO-1270 Safety and efficacy of switching to besifovir dipivoxil maleate in virologically-suppressed chronic hepatitis B patients with tenofovir disoproxil fumarate: 24-week interim analysis Hyung Joon Yim Received Received
  PO-1278 Does continuing anticoagulation increase the risk of bleeding during variceal band ligation in patients with portal hypertension? A meta-analysis and systematic review Mark Muthiah Received Received
  PO-1285 An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome Rakesh K Raman Received Received
  PO-1286 No emergent core inhibitor resistance in patients with chronic hepatitis B virus infection treated with Vebicorvir in combination with a nucleos(t)ide reverse transcriptase inhibitor Gregory Suess Received Received
  PO-1289 Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after direct-acting hepatitis C therapeutics corresponded to a lower incidence rate of hepatocellular carcinoma (HCC) below the cost-effective threshold for surveillance Winston Dunn Received Received
  PO-1294 Implementation of a national registry for patients with primary biliary cholangitis (PBC): The German PBC cohort Johannes Wiegand Received Received
  PO-1296 Pruritus, anxiety, and depression in patients with nonalcoholic fatty liver disease Albrecht Boehlig Received Received
  PO-1304 Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma Darko Castven Received Received
  PO-1305 Mechanism of Action of Hepatitis B Virus S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) Molecules. C. Cheng Kao Received Received
  PO-1307 High rate of early HCV reinfection among PWID with high-risk practices and re-treatment efficacy Sabela Lens Received Received
  PO-1309 Alanine aminotransferase flares and seroclearance in chronic hepatitis B virus patients Shahed Iqbal Received Received
  PO-1311 The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis Aharon Aharon Received Received
  PO-1312 The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment Lorenz Balcar Received Received
  PO-1314 The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial Reshma Shringarpure Received Received
  PO-1316 Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced chronic liver disease Lorenz Balcar Received Received
  PO-1330 Performance of screening strategies for primary prophylaxis of variceal bleeding in patients with compensated cirrhosis: a cost-effectiveness analysis Shanshan Lin Received Received
  PO-1333 Osteopontin expression identifies a subset of macrophages distinct from Kupffer Cells in the fatty liver Anneleen Remmerie Received Received
  PO-1334 Mild alcohol consumption and risk for cardiovascular disease in patients with non-alcoholic steatohepatitis: data from a multicenter observational study. Savvoula Savvidou Received Received
  PO-1335 Metabolomic predictive models in the diagnosis of drug-induced liver injury Daniel E. Di Zeo-Sánchez Received Received
  PO-1336 The liver fibrosis marker PRO-C3 increases with fibrosis stage and is neither elevated in diabetics without liver disease nor in healthy obese subjects Diana Julie Leeming Received Received
  PO-1339 Impact of the COVID-19 pandemic on hepatitis C virus screening in drug treatment settings in England and implications for testing protocols Shayon Salehi Received Received
  PO-1340 Association between chronic hepatitis B infection and COVID-19: A nationwide case-control study Seong Hee Kang Received Received
  PO-1341 Active search to retrieve lost-to follow-up HCV patients (RELINK-C strategy): health and economic value Raquel Domínguez-Hernández Received Received
  PO-1346 Double negative T cells mediate CD39-dependent protection in hepatic ischemia and reperfusion injury Hua Jin Received Received
  PO-1351 Preliminary experience on safety of cabozantinib in recurrent hepatocellular carcinoma after liver transplantation. A case series federica invernizzi Received Received
  PO-1352 Study on the mechanism of chemokine CCL21 mediating IRBIT in the malignant biological behavior of liver cancer Jianhong Ding Received Received
  PO-1353 Randomized controlled study:investigation of the effcet of exercise on liver function tests,fatigue and quality of life in patients with liver cirrhosis Hlya Keskin Received Received
  PO-1354 Wilson Disease is associated with prevalent neuropsychiatric comorbidity Eva-Doreen Pfister Received Received
  PO-1356 Hypoxia-induced liver angiogenesis rescues survival upon small for size hepatectomy in mice Maxime De Rudder Received Received
  PO-1357 Role of ASCT2 and KGA for ammonia-induced astrocyte senescence Olivia Knappe Received Received
  PO-1359 Anti-oxidant, anti-inflammatory, and anti-fibrotic properties of triterpenic acids and phenylpropanoids on in vitro models of non-alcoholic steatohepatitis Noel Salvoza Received Received
  PO-1364 Is it the scale (rather than the nature) of the inflammatory response in autoimmune hepatitis that determines treatment response? Jessica Dyson Received Received
  PO-1369 Non-alcoholic fatty liver disease in a rodent model of bariatric surgery with different bypass lengths Paula Richwien Received Received
  PO-1374 Optimizing diagnostic algorithms to advance HCV elimination in Italy: A cost effectiveness evaluation Loreta A. Kondili Received Received
  PO-1375 Alcohol consumption and the interest in reducing it among patients with alcohol-related liver disease: a national health survey Anna Emilie Kann Received Received
  PO-1379 Enrichment of CXCR3CD27CD161 NK cells in autoimmune and drug induced liver injury Amber Bozward Received Received
  PO-1385 Risk of Hepatitis B Virus Reactivation in Patients Treated with Immunotherapy for Anti-cancer Treatment Sun Yoo Received Received
  PO-1386 Capsid assembly modulator ALG-000111 and its prodrug ALG-000286 display excellent in vitro and in vivo antiviral activity Yannick Debing Received Received
  PO-1387 Plasma Soluble CD14 predicted development of hospital acquired infection in decompensated cirrhosis patients from the ATTIRE trial Louise China Received Received
  PO-1389 Effect of corticosteroids in the outcome of drug-induced liver injury: a propensity score matched study Hao Niu Received Received
  PO-1397 Community-based linkage to care program targeting HCV elimination - Estalishment of a model towards HCV elimination in china. Ming Li Received Received
  PO-1404 Metabolomic changes in HIV/HCV coinfected patients after DAAs therapy Óscar Brochado Received Received
  PO-1415 Usefulness of dried blood spot samples for HCV genotyping to inform retreatment after recurrent viremia in people who inject drugs in the real world Elisa Martró Received Received
  PO-1416 Pharmacokinetics and safety of JNJ-73763989, an RNA interference therapy for hepatitis B virus, in moderately hepatically impaired participants Thomas Kakuda Received Received
  PO-1418 Risk of primary biliary cholangitis in first degree relatives: a prospective cohort study johannes hartl Received Received
  PO-1419 First real-life experiences with 2 mg bulevirtide for the treatment of hepatitis delta - data from a tertiary reference centre in Germany Caroline Zllner Received Received
  PO-1420 Molecular markers of response to anti-pd1 therapy in advanced hepatocellular carcinoma Philipp Haber Received Received
  PO-1421 The 2010 HIV outbreak among people who inject drugs in Athens, Greece could have been prevented if the undetected 2009 HCV outbreak had been detected: A mathematical modeling study Ilias Gountas Received Received
  PO-1422 Longitudinal monitoring of bioengineered whole liver constructs using a novel perfusion bioreactor Sara Campinoti Received Received
  PO-1426 A discrete choice experiment about patients and clinicians preferences for the meet-test-treat approach to HCV management Patrizio Pasqualetti Received Received
  PO-1428 The measurement properties of the PBC-40: a Dutch validation study Rozanne de Veer Received Received
  PO-1429 Clinical and prognostic differences between non-alcoholic fatty liver disease and mixed fatty liver disease Nicolau Vallejo-Senra Received Received
  PO-1431 Value assessment of sofosbuvir-based regimens for (chronic) hepatitis C in Spain Raquel Domínguez-Hernández Received Received
  PO-1436 Ultra- processed food is associated with features of the metabolic syndrome and NAFLD Dana Ivancovsky Wajcman Received Received
  PO-1441 Characterization and study of hepatic stellate cells in a 3D bioengineered model of fibrosis Sara Campinoti Received Received
  PO-1448 Excellent virological and clinical responses maintained over 3 years of continuous Bulevirtide treatment in patients with HDV compensated cirrhosis and clinically significant portal hypertension Alessandro Loglio Received Received
  PO-1449 Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients Beatriz Mateos Muñoz Received Received
  PO-1450 Secreted hepatitis B virus (HBV) RNA associates to extracellular vesicles in supernatant of infected hepatocytes Delphine Bousquet Received Received
  PO-1451 Characterization of circulating hepatitis B virus (HBV) RNA in chronic hepatitis B (CHB) patients doohyun kim Received Received
  PO-1453 Screening for non-alcoholic fatty liver disease (NAFLD)-related advanced fibrosis, real life data and comparison of two endocrinology-hepatology referral strategies Cyrielle Caussy Received Received
  PO-1459 Recipient age influences the short- and long-term survival after liver transplant: results of the French national cohort 2007-2017 marianne Latournerie Received Received
  PO-1460 Harnessing liver-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma Nekisa Zakeri Received Received
  PO-1462 Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis Francis Teh Received Received
  PO-1471 Myostatin is associated with sarcopenia and in combination with creatinine phosphokinase or albumin may be used as a screening tool of sarcopenia in liver cirrhosis Theodoros Alexopoulos Received Received
  PO-1472 CD4 T cell tolerance induced by nanoparticle-mediated autoantigen delivery to liver sinusoidal endothelial cells depends on interferon-gamma Daria Krzikalla Received Received
  PO-1474 A new strategy to screen varices needing treatment via risk ranked from 0 to 100 by VARS and VANT tests Paul Calès Received Received
  PO-1480 Epidemiological evaluation of the liver cirrhosis in Albania: comparison with the historical data and indications to antiviral treatment appropriateness Xhimi Tata Received Received
  PO-1484 Prevalence of immunological tolerance among type 1 autoimmune hepatitis patients on long-term remission Maria Carlota Londoño Received Received
  PO-1486 Patient perspective on treatment and prognosis in Primary Biliary Cholangitis: a descriptive study Maria van Hooff Received Received
  PO-1496 Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis Simone Incicco Received Received
  PO-1500 Dose adjustment of chelators based on urinary copper excretion after a drug free holiday - the first step to personalized medicine in patients with Wilson disease Karin Kozbial Received Received
  PO-1501 Ascitic fluid lactic acid is an accurate predictor of mortality in patients with spontaneous bacterial peritonitis Theodoros Alexopoulos Received Received
  PO-1504 An independent blinded review of suspected drug-induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatoxicity review committee (SHRC) Paul Watkins Received Received
  PO-1505 Fibrosis Biomarkers CA15-3 and Thrombospondin-2 are Associated with Higher Hepatic Collagen Content in Non-alcoholic Steatohepatitis (NASH)-related Fibrosis Carey Escheik Received Received
  PO-1508 Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs Ryan Buchanan Received Received
  PO-1510 Serum markers of HBV cccDNA transcriptional activity - HBcrAg and pre-genomic HBV RNA, pre-treatment HDV RNA and HDV genotype are useful markers in predicting treatment responses to pegylated interferon in HDV infection Ivana Carey Received Received
  PO-1512 Multimarker analysis combining markers of fibrosis and inflammation in primary sclerosing cholangitis Guri Fossdal Received Received
  PO-1518 Serum metabolomics-based steatohepatitis score for the non-invasive identification of patients with non-alcoholic steatohepatitis (NASH) in multiethnic, including type 2 diabetes mellitus population Pablo Ortiz Received Received
  PO-1519 Endoscopic surveillance of esophageal varices could be refined in HBV compensated cirrhotics taking Tenofovir or Entecavir: an 11-year real-life study Elisa Farina Received Received
  PO-1522 Voices of italian patients with Wilsons disease: results from a quality survey Viviana Anelli Received Received
  PO-1523 Significantly higher mortality post liver transplantation in patients with psychosocial risk factors Jeevan Barn Received Received
  PO-1525 Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment Gemma Iserte Received Received
  PO-1526 The natural history of pediatric Non-alcoholic Fatty Liver Disease: a long term follow up study Laura Draijer Received Received
  PO-1541 Potential underlying mechanisms in the immune response to COVID in obese heavy drinkers Martí Ortega Ribera Received Received
  PO-1542 Metabolic comorbidities reduce the improvement of procoagulant imbalance in non-cirrhotic patients with chronic hepatitis C (CHC) after viral eradication with direct-acting antiviral agents (DAAs) Giordano Sigon Received Received
  PO-1547 Steatosis, inflammasome upregulation and fibrosis are attenuated in microRNA-155 deficient mice in a diet-induced model of NASH Mrigya Babuta Received Received
  PO-1549 Circulating microRNAs profiling in acute decompensation of liver cirrhosis Yasmina Chouik Received Received
  PO-1551 The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry Carey Escheik Received Received
  PO-1553 Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-December 2020 Tengiz Tsertsvadze Received Received
  PO-1558 Hepatobiliary Changes in Intestinal Disorders Jessica Voss Received Received
  PO-1561 Risk of hepatocellular carcinoma after HCV eradication: capturing the role of portal hypertension Elton Dajti Received Received
  PO-1563 Longer-term Outcome from Alcoholic Hepatitis: survival, re-admission rate and out-patient attendance after discharge Ewan Forrest Received Received
  PO-1568 Longitudinal variability of noninvasive tests of fibrosis: Implications for treatment response monitoring in patients with NASH Andrew Billin Received Received
  PO-1572 Screening and treatment of Hepatitis C virus in Hungarian prisons: 13 years of experience Magyar Alapítvány Received Received
  PO-1574 MARC1 p.A165T polymorphism is associated with decreased liver injury and enhanced antioxidant activity in serum in patients with AIH Maciej Janik Received Received
  PO-1575 Fibrosis response assessed by enhanced liver fibrosis and FibroScan liver stiffness measurement in patients with non-alcoholic steatohepatitis treated with subcutaneous semaglutide Quentin Anstee Received Received
  PO-1578 Should normal liver blood tests be the treatment target in primary biliary cholangitis? Aaron Wetten Received Received
  PO-1579 Chinese traditional medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via the YAP/TAZ signaling Wen Zhao Received Received
  PO-1580 Prospective screening of significant liver fibrosis in a large cohort of 131,861 French subjects using, since October 2020, automatic calculation of FIB-4 in routine blood tests. DENIS OUZAN Received Received
  PO-1588 Comorbidity and healthcare utilization burden of patients diagnosed with non-alcoholic steatohepatitis based on fibrosis-4 score severity Christine Coco Received Received
  PO-1589 Non-alcoholic steatohepatitis-related costs changes in the context of fibrosis progression status in European patients Leonardo Ruiz Casas Received Received
  PO-1593 The Caserta Model: a way for HCV free Hospitals, a simplified procedure for HCV micro-elimination vincenzo messina Received Received
  PO-1598 Investigating the potential association of elevated plasma Leukotriene B4 and survival in females in the ATTIRE trial Thais Helena Tittanegro Received Received
  PO-1605 Detection of novel biomarkers in HBV-associated chronic hepatitis, liver fibrosis/cirrhosis, and hepatocellular carcinoma utilizing transcriptome sequencing technology Dandan Zhao Received Received
  PO-1606 FXR agonists increase liver-derived serum alkaline phosphatase (ALP) by species-specific pharmacologic mechanisms independent of cholestasis Justin Schumacher Received Received
  PO-1609 The impact of liver fibrosis progression on the Health-related quality of life of patients with non-alcoholic steatohepatitis in clinical practice in Europe Leonardo Ruiz Casas Received Received
  PO-1613 Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease Katharina Pomej Received Received
  PO-1615 Role of cytosolic phospholipase A2 and 5-lipoxygenase for ammonia-induced astrocyte senescence Philipp Heimers Received Received
  PO-1622 Efficacy of hepatitis B virus vaccines HBVaxpro40 and Fendrix in patients with chronic liver disease in clinical practice Diana Horta Received Received
  PO-1623 Treatment of alcohol withdrawal syndrome in patients with alcohol-related liver disease Alexander Doyle Received Received
  PO-1624 Planning the Hepatitis C elimination in Cyprus: A modeling study Ilias Gountas Received Received
  PO-1626 Rilpivirine-induced anti-inflammatory effects in non-alcoholic fatty liver disease involve the inhibition of CCL2/CCR2 axis Ángela B. Moragrega Received Received
  PO-1628 Comparison of hepatitis B virus relapses between hepatitis B e antigen-negative chronic hepatitis B patients who discontinue tenofovir disoproxil fumarate with or without switching to alafenamide Chien--Hung Chen Received Received
  PO-1629 Influence on cancer cell energy metobolism by pharmocological inhibition of the histone modifying lysine-specific demethylase 1 Jie Wang Received Received
  PO-1631 A cell culture model of primary human hepatocytes derived from HBV-infected humanized mice for antiviral drug evaluation Jan-Hendrik Bockmann Received Received
  PO-1641 Long-term treatment with odevixibat improves multiple sleep parameters in patients with progressive familial intrahepatic cholestasis: a pooled responder analysis from the phase 3 PEDFIC studies Julie Collins Received Received
  PO-1643 Nutritional supplementation with B-Hydroxy-B-methylbutyrate (HMB) in malnourished cirrhotic patients Silvia Espina Received Received
  PO-1644 A deep learning approach to analysis of MRCP images predicts clinical events and progression to cirrhosis in patients with primary sclerosing cholangitis AADITYA PRAKASH Received Received
  PO-1648 Clinical utility of 30 relative decline in MRI-PDFF in predicting fibrosis regression in nonalcoholic fatty liver disease Nobuharu Tamaki Received Received
  PO-1649 Acute liver injury results in temporal changes in hepatic macrophage pool Anna Bujko Received Received
  PO-1651 Histological lesions can predict response to corticosteroids in patients with severe alcohol-related steatohepatitis Carolin Lackner Received Received
  PO-1653 Sustained delivery of IL-10 using an innovative cell-based platform for immune-mediated hepatitis Sofia Brites Boss Received Received
  PO-1654 Changes in alcohol-related liver disease admissions over the time of minimum unit pricing of alcohol: the GRI Q4 study Sardar Chaudhary Received Received
  PO-1661 Outcomes and characteristics of hepatocellular carcinomas (HCC) in Caucasian chronic hepatitis B (CHB) patients treated with long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy George Papatheodoridis Received Received
  PO-1664 Incidence of hepatic outcomes in patients with cirrhosis due to primary biliary cholangitis: A population-based epidemiology study Christine Coco Received Received
  PO-1665 Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies Julie Collins Received Received
  PO-1666 Telemedicine improve HCV elimination among Italian people who use drugs: an innovative therapeutic model to increase the adherence to treatment into addiction care centers. Valerio Rosato Received Received
  PO-1667 Elevated serum bile acids in NASH patients with fibrosis in the context of their cholestatic genetic predisposition Monika Rau Received Received
  PO-1668 Extracorporeal non-invasive assessment of the hepatobiliary function using novel bile acid derivatives with near-infrared fluorescence Jose Marin Received Received
  PO-1670 Use of rifaximin is not associated with infections by multi-drug resistant bacteria, but with occurrence of rifampicin-resistance in coagulase-negative staphylococci Lina Marise Schulte Received Received
  PO-1684 Low-grade hyperammonemia induces severe neuronal mitochondrial dysfunction in cellular and animal models of hepatic encephalopathy Annarein Kerbert Received Received
  PO-1688 Insights on the antiviral mechanisms of action of a TLR1/2 agonist in hepatitis B virus infected hepatocytes Manon Desmares Received Received
  PO-1689 Combination treatment with cilofexor and firsocostat leads to improvements in the FibroScan-AST (FAST) score in patients with advanced fibrosis due to NASH Rohit Loomba Received Received
  PO-1691 Feasibility and effectiveness of models of hepatitis C viremia testing at harm reduction sites in Georgia: a prospective 3 arm study Maia Japaridze Received Received
  PO-1693 Frailty in non-alcoholic fatty liver cirrhosis in comparison to alcoholic cirrhosis, risk patterns and impact on prognosis Tomas Koller Received Received
  PO-1696 Diagnostic Accuracy of Transient Elastography in Diagnosing Clinically Significant Portal Hypertension in Patients with Chronic Liver Disease: A Systematic Review and Meta-analysis Ashish Kumar Received Received
  PO-1699 Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of hepatitis B virus (HBV) infection Glen Coburn Received Received
  PO-1701 Low incidence of SARS-CoV-2 infection in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a German tertiary center during the 2020 pandemic Lilith Kuballa Received Received
  PO-1705 Application of a machine learning model to improve performance of endoscopic classification for prediction bleeding in patients with compensated cirrhosis with esophageal varices Samagra Agarwal Received Received
  PO-1707 Cloning and in vivo characterization of a new hepatitis D virus genotype 1 strain from a patient achieving sustained virus response to interferon alpha treatment Katja Giersch Received Received
  PO-1708 Hallmarks of neutrophil extracellular trap (NET) components in the course of alcoholic liver disease Anna Rycyk Received Received
  PO-1711 Inducers of the NF-kB pathways impair Hepatitis Delta virus (HDV) replication & strongly decrease progeny infectivity and spreading Julie Lucifora Received Received
  PO-1712 Baseline liver volume is a major prognostic factor in acute decompensation of alcohol-associated cirrhosis: results from the prospective multicentre PROLIV study José Ursic-Bedoya Received Received
  PO-1713 Changes in Liver Transplant Wait-List Trends in Young American Adults: 2003-2018 George Philip Received Received
  PO-1714 Liver stiffness by vibration-controlled transient elastography predicts disease progression in patients with advanced fibrosis due to NASH Rohit Loomba Received Received
  PO-1718 Genetic analysis and phenotypic correlation in ductal plate malformation Meha Bhuva Received Received
  PO-1722 Epidemiology and burden of Progressive Familial Intrahepatic Cholestasis: Systematic review Velichka Valcheva Received Received
  PO-1725 Health-related quality of life and stigma related to chronic hepatitis B: a systematic literature review Vera Gielen Received Received
  PO-1727 Combination therapy of lanifibranor and firsocostat further improves steatohepatitis and fibrosis compared to monotherapy in a diet-induced murine model of NASH Guillaume Wettstein Received Received
  PO-1729 Risk based HCC surveillance has the potential to minimise patient harm Chris Curran Received Received
  PO-1730 Cirrhotic patients without prior antibiotic exposure may be eligible to lower first-line antibiotic strategies for nosocomial infections: results from a local antibiotic resistance study Fanny Lebossé Received Received
  PO-1745 Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment Thorben Frndt Received Received
  PO-1747 Spleen size does not correlate with histological stage of liver disease in people with non-alcoholic fatty liver disease Tessa Cacciottolo Received Received
  PO-1748 Improvement in itch correlates with improved sleep in GLIMMER, a Phase 2b trial of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis David Jones Received Received
  PO-1752 Human antigen R (HuR) SUMOylation fine-tunes hepatocellular carcinoma (HCC) progression by modulating the expression of mitochondrial mRNAs Sofia Lachiondo-Ortega Received Received
  PO-1753 Implication of the Patatin-like phospholipase domain-containing 3 I148M mutation on hepatic stellate cells mitochondrial dysfunction and profibrogenic potential Elisabetta Caon Received Received
  PO-1755 Younger age is associated with lower self-reported quality of life among patients with autoimmune disease during Canadas response to the COVID-19 pandemic Christina Plagiannakos Received Received
  PO-1758 Circulating Fn14 is associated with pathogenic TH17 polarization in children with sclerosing cholangitis and inflammatory bowel disease Simon Lam Received Received
  PO-1762 Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, metabolism, and in histologic parameters following treatment with efruxifermin Erik Tillman Received Received
  PO-1763 Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathyShort title: RIFSYS Trial Debbie Shawcross Received Received
  PO-1766 High risk medication-related problems are associated with lower quality of life in decompensated cirrhosis Kelly Hayward Received Received
  PO-1767 The prevalence of sarcopenia and myosteatosis in cirrhotic patients: preliminary results from an italian multicenter study (EpatoSarco Group) Simone Di Cola Received Received
  PO-1771 The expressions of CCNB1, CDC20 and CENPF is both peripheral blood and liver is associated with anti-tumour immunity in HCC Zhenlin Huang Received Received
  PO-1773 Clinical value of surveillance biopsies in pediatric liver transplantation: A single center experience with 800 biopsies Brittany Rocque Received Received
  PO-1775 GST-HG141, a novel clinical-stage hepatitis B virus capsid assembly modulator Vadim Bichko Received Received
  PO-1777 The Metabolomics of Non-Alcoholic Fatty Liver Disease: Of Networks and Biomarkers Aidan McGlinchey Received Received
  PO-1781 HCC incidence is low after HBsAg seroclearance in off-Nuc patients Rachel Wen-Juei Jeng Received Received
  PO-1787 Markers of neutrophil extracellular traps are elevated in patients with Child-Pugh B and C liver cirrhosis Robin Zenlander Received Received
  PO-1788 The incidence and predictors of HCC in REVEAL chronic hepatitis B patients with incident spontaneous HBsAg loss Rachel Wen-Juei Jeng Received Received
  PO-1789 Characterization of the Liver Immune Microenvironment in Chronic HBV Infected Patient Liver Biopsies Nicholas Van Buuren Received Received
  PO-1790 National audit of diagnosis, management and surveillance in primary sclerosis cholangitis (PSC) in the United Kingdom. Evangelia Fatourou Received Received
  PO-1791 Hepatic decompensation and hepatocellular carcinoma after stopping nucleos(t)ide analogue therapy: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study) Grishma Hirode Received Received
  PO-1797 Effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in a diet-induced obese (DIO) mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis Charles McWherter Received Received
  PO-1799 Among cancer patients, autoimmune hepatitis with cirrhosis increases mortality Morten Daniel Jensen Received Received
  PO-1801 Evolutionary learning derived clinical-radiomic models for predicting early recurrence of hepatocellular carcinoma after surgical resection I-Cheng Lee Received Received
  PO-1809 Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Stuart C Gordon Received Received
  PO-1811 Odevixibat effects on cholestasis-related parameters: Analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies in children with progressive familial intrahepatic cholestasis Julie Collins Received Received
  PO-1813 General population testing for hepatitis B in Australia: a cost-effectiveness analysis Yinzong Xiao Received Received
  PO-1817 Decreased hepatitis B and C testing in Ontario, Canada during the first wave of the COVID-19 pandemic Erin Mandel Received Received
  PO-1819 KS-356, a novel inhibitor of TGF-beta superfamily signaling, improves obesity and obesity-related hepatic steatosis by inhibition of TGF-beta/Smad3 signaling pathway in high-fat diet-induced mice Kisoo Pahk Received Received
  PO-1822 Cellular immune responses to human betaretrovirus in patients with primary biliary cholangitis Hiatem Abofayed Received Received
  PO-1823 Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease: a nationwide cohort study Min Na Kimi Received Received
  PO-1825 Programmed Death-Ligand 1 protein is preferentially expressed in tumor-associated macrophages in peritumoral regions of hepatocellular carcinoma Pil Soo Sung Received Received
  PO-1826 Agreement in non-invasive fibrosis risk assessments in a primary care NAFLD cohort Andrew Schreiner Received Received
  PO-1828 Genetic mutation and cystic fibrosis-associated liver disease at the time of diagnosis in children: A correlational study ALEJANDRA SABILLON Received Received
  PO-1831 Combinations of an acetyl CoA carboxylase inhibitor, FXR agonist and GLP-1R agonist inhibits fibrosis progression in the rat choline-deficient, L-amino acid defined, high-fat diet model of advanced fibrosis ARCHANA VIJAYAKUMAR Received Received
  PO-1833 Odevixibat therapy improves clinically meaningful endpoints in children with progressive familial intrahepatic cholestasis: Data from the PEDFIC 1 and PEDFIC 2 trials Julie Collins Received Received
  PO-1837 HBsAg, anti-HBs and ALT kinetic characterization during NAP-based combination therapy of HBeAg negative chronic hepatitis B infection Harel Dahari Received Received
  PO-1839 The Association of Dietary Factors and Physical Activity with Sarcopenia in Non-Alcoholic Fatty Liver Disease (NAFLD) Carey Escheik Received Received
  PO-1841 Earlier and more frequent virological and clinical relapse after cessation of tenofovir disoproxil fumarate versus entecavir therapy: Results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study) Hannah Choi Received Received
  PO-1843 Pretreatment serum bile acid parameters and predictability of response to odevixibat, an ileal bile acid transport inhibitor, in children with progressive familial intrahepatic cholestasis Julie Collins Received Received
  PO-1849 A3907, a novel orally available inhibitor of the apical sodium-dependent bile acid transporter, improves key clinical markers of non-alchoholic steatohepatitis in obese diet-induced and biopsy-confirmed mouse models PETER AKERBLAD Received Received
  PO-1851 Significant lipid lowering by ASC41oral tablet,a liver targeted THR agonist,in a phase I randomized,double-blind,placebo controlled single- and multiple-ascending dose study Mingfei Ge Received Received
  PO-1856 Anti-tumor activity of TRN-000546, a liver-distributed monophosphate prodrug of FdUMP, in orthotopic liver tumor models Kevin Klucher Received Received
  PO-1857 AI digital pathology using qFibrosis reveals heterogeneity of fibrosis regression in hepatitis B and C patients with SVR Feng Liu Received Received
  PO-1862 Predictors of loss to follow-up in an outpatient cirrhotic population Joana Vieira Barbosa Received Received
  PO-1865 Association between non-alcoholic fatty liver disease and extrahepatic malignancy Mesut GM&350;SOY Received Received
  PO-1871 Screening, enhancement of access to care and prioritization of treatment of chronic hepatitis C infection in high-risk population in Hong Kong Lung-Yi Loey Mak Received Received
  PO-1872 A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison Anna Palmer Received Received
  PO-1876 Novel shapelet patterns for time series classification (TSC) for AFP and ALT to predict HCC in patients with chronic hepatitis B on antiviral treatment Vicki Hui Received Received
  PO-1877 Feasibility, effectiveness, and lessons learned from the introduction of decentralised HCV testing and treatment at primary healthcare clinics in three regions in Malaysia Xiao Hui Sem Received Received
  PO-1880 Association between Non-alcoholic Fatty Liver Disease and the Risk of Dementia: A Nationwide Cohort Study Gi-Ae Kim Received Received
  PO-1885 ALKBH5-modified HMGB1-STING activation contributes to radiation-induced liver disease via innate immune response Genwen Chen Received Received
  PO-1895 Evaluation of the Fibrosis-4 score for referral from primary care patients for NAFLD in Belgium Leen Heyens Received Received
  PO-1897 Men and women display different predictive biomarkers of NASH: a machine learning approach Gerard Baiges Gaya Received Received
  PO-1899 A novel liver-specific fibrosis biomarker, PRO-C18L, can predict response to antifibrotic treatment, with a peroxisome proliferator activated receptor -y agonist, in patients with chronic hepatitis C Ida Villesen Received Received
  PO-1904 Low skeletal muscle mass is a potential risk factor for lean non-alcoholic fatty liver disease in patients with non-alcoholic fatty liver disease Min Kyu Kang Received Received
  PO-1907 Viral interference in a hepatitis C virus and hepatitis E virus co-infection system Thomas Burkard Received Received
  PO-1908 Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR- Agonist, in HIgh Fat Diet Induced NASH SD Rats weifeng shi Received Received
  PO-1916 Co-stimulatory signals mediated by ICOS/ICOS-L dyad influence the differentiation of liver NASH-associated macrophages (NAMs) Laila Lavanya Gadipudi Received Received
  PO-1917 Significant in-Vitro and in-Vivo inhibition of HBsAg and HBV pgRNA with ASC42,a novel non-steroidal FXR agonist flutter ger Received Received
  PO-1918 The impact of hepatitis C virus eradication on hepatocarcinogenesis in haemophiliacs Yosuke Inukai Received Received
  PO-1919 Long term follow-up in HCV infected patients with end stage chronic kidney disease after DAA therapy Joan Martínez-Campreciós Received Received
  PO-1927 In vivo SPECT imaging of steatohepatitis in NAFLD preclinical models using VCAM-1 nanobody: a proof-of-concept study Maxime Nachit Received Received
  PO-1928 Unexpected rising in the circulation of HBV complex profiles with HBsAg vaccine-escape mutations in HBV genotype-D: potential implications for HBsAg detection/quantification and vaccination strategies Lorenzo Piermatteo Received Received
  PO-1929 Discovery of conserved HDV-specific CD8 T-cell epitopes in HDV/HBV co-infection Valerie Oberhardt Received Received
  PO-1930 Albumin dysfunction correlates with disease markers in patients with decompensared cirrhosis Raquel Horrillo Received Received
  PO-1932 Results of a screening program of liver fibrosis with transient elastography in subjects with alcohol use disorder EMMA AVITABILE Received Received
  PO-1935 The hepatoprotective role of the antiretroviral drug Rilpivirine is associated with altered autophagy in in vitro and in vivo models of liver fibrosis Federico Lucantoni Received Received
  PO-1936 A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination Jeffrey V Lazarus Received Received
  PO-1942 Blockade of IL-1 signaling in hepatocytes reduces tumor growth in a mouse model of NAFLD-related HCC Nadine Gehrke Received Received
  PO-1947 Etiology and clinical characteristics of acute hepatitis in South Korea: A prospective, multicenter Study Gwang Hyeon Choi Received Received
  PO-1949 Role of hypoxia-inducible factors 1alpha and 2alpha in prognosis and sorafenib chemoresistance in hepatocarcinoma Carolina Méndez-Blanco Received Received
  PO-1950 An antibody microarray identifies epidermal growth factor receptor as a novel host factor of hepatitis E virus Jil Alexandra Schrader Received Received
  PO-1951 Metabolic dysfunction Associated Fatty Liver Disease improves detection of high liver stiffness: The Rotterdam Study Laurens Van Kleef Received Received
  PO-1957 Resistance to sorafenib in hepatocarcinoma: role of BCL2 interacting protein 3 promoter hypermethylation Paula Fernández-Palanca Received Received
  PO-1961 Significant improvement of NAFLD activity scores and liver fibrosis by ASC42,a novel non-steroidal FXR agonist,in high fat diet induced NASH mice Mingfei Ge Received Received
  PO-1962 Validation of a simple score to identify patients who can safely use protease inhibitor-based therapy for HCV infection Lisette Krassenburg Received Received
  PO-1966 Hepatitis C elimination in the Netherlands (CELINE): nationwide retrieval of lost to follow-up chronic hepatitis C patients is feasible and worthwhile Marleen van Dijk Received Received
  PO-1969 Abnormal glycosphingolipid patterns in human cholangiocarcinoma stem-like subset Mirella Pastore Received Received
  PO-1971 Factors associated with unplanned intensive care unit readmission following liver transplantation Marcus Robertson Received Received
  PO-1980 Quantified integrated hepatitis B virus DNA is related to viral activity in chronic hepatitis B patients Robin Erken Received Received
  PO-1981 Non-invasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients Mona Munteanu Received Received
  PO-1982 Association between plasma miRNA-200-3p and transcriptional activity of hepatic cccDNA in chronic hepatitis B. Vladimir Loukachov Received Received
  PO-1983 HLA-B27-restricted CD8 T-cell response against hepatitis B virus: viral escape as central mechanism of T-cell failure Elahe Salimi Alizei Received Received
  PO-1986 The rs599839 AG variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients Marica Meroni Received Received
  PO-1987 Carvedilol improves risk of decompensation and survival in compensated cirrhosis. A competing-risk meta-analysis of individual patient data Candid Villanueva Received Received
  PO-1990 The unmet needs of living with non-alcoholic steatohepatitis (NASH) in Europe and Canada: results from a multi-country survey Jeffrey V Lazarus Received Received
  PO-1996 HBV reactivation can be predicted by combined highly-sensitive HBV markers: implications for an optimized management of HBsAg-negative/anti-HBc-positive oncohematological patients Mohammad Alkhatib Received Received
  PO-1998 A study evaluating outcomes of cirrhotic patients managed virtually in a specialist liver cirrhosis service due to the COVID crisis. Alex Cole Received Received
  PO-2001 Covid - 19 in Liver Transplant Recipients: A National Cohort Gkhan Kabaam Received Received
  PO-2006 Anti-inflammatory and anti-fibrotic effects of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis David Fraser Received Received
  PO-2008 Sequential non-invasive assessments improve predictability for liver-related events in direct antivirals-treated chronic hepatitis C patients Yen-Chun Liu Received Received
  PO-2010 Ethanol induced alterations in intestinal microbiota correlate with decreased intestinal nuclear receptor (PXR) pathway related proteins Sudrishti Chaudhary Received Received
  PO-2014 The emergency department, a new setting for HBV screening in populations with limited linkage to the health care system in a high-income country Jordi Llaneras Received Received
  PO-2015 Immunological Background Pinpoints Patients at High Risk of Immune-related Hepatitis Recurrence during Check-points Inhibitors Rechallenge Ana Barreira Received Received
  PO-2020 Good practice hepatitis C screening and linkage to care initiatives at the SLTC Summit 2020: three out of four diagnosed patients able to start direct-acting antiviral treatment Joaquin Cabezas Received Received
  PO-2021 Deferred direct-acting antiviral treatment in kidney transplantation from HCV-viremic donors into HCV-negative recipients. Giulia Pagano Received Received
  PO-2030 Screening of advanced liver fibrosis in patients with coronary arterial disease, the CORONASH Study thierry thevenot Received Received
  PO-2032 Disclosure of non-alcoholic steatohepatitis (NASH) diagnosis and fear of discrimination: results from a multi-country survey Jeffrey V Lazarus Received Received
  PO-2033 TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models Miriam Longo Received Received
  PO-2039 Anticipated timing of hepatitis C virus elimination in the Netherlands and the impact of COVID-19 Marleen van Dijk Received Received
  PO-2040 Single-centre experience with follow up of patients with acute porphyria Barbora Nováková Received Received
  PO-2043 The role of miR-873-5p in Alcohol-related Liver Disease Rubén Rodríguez Agudo Received Received
  PO-2047 HCV screening of immigrants at arrival: an opportunity to linkage to care of a population with limited access to health care system Mar Riveiro Received Received
  PO-2048 Rapid point of care HCV testing allows high throughput HCV screening and rapid treatment uptake among PWID attending a medically supervised injecting room Michael MacIsaac Received Received
  PO-2055 The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in Non-alcoholic Fatty Liver Disease (NAFLD) patients gains value Erika Paolini Received Received
  PO-2058 Mesenchymal Stem Cell Transplantation in patients with cirrhosis and acute-on-chronic liver failure: A randomized, double-blind placebo control trial. Enric Reverter Received Received
  PO-2059 Characterizing stigma related to non-alcoholic fatty liver disease (NAFLD) and obesity: a Twitter discourse analysis Jeffrey V Lazarus Received Received
  PO-2070 Discriminatory changes in circulating lipid and small molecule metabolites in patients with MAFLD associated hepatocellular cancer Rohini Sharma Received Received
  PO-2074 Systematic review with meta-analysis: Non-Alcoholic Fatty Liver Disease (NAFLD) in Pregnancy Hydar El Jamaly Received Received
  PO-2075 Aspirin and the risk of hepatocellular carcinoma in chronic liver disease: A systematic review and meta-analysis Jin Lin Tan Received Received
  PO-2081 Feasibility, effectiveness, and lessons learnt from decentralized HCV testing and treatment models among the general population in Delhi, India Sonjelle Shilton Received Received
  PO-2089 HIF1a-mediated RelB/APOBEC3B downregulation allows Hepatitis B virus persistence Tobias Riedl Received Received
  PO-2090 A 3-proteomic score to improve the clinical management of childhood liver cancer Carolina Armengol Received Received
  PO-2093 Micro-elimination of hepatitis C achieved in HIV co-infected persons in Slovenia: analysis of HCV infection in a national HIV cohort Jasna Cernosa Received Received
  PO-2094 Quantitate MR can identify paediatric patients with quiescent disease who may benefit from a change in treatment Elizabeth Shumbayawonda Received Received
  PO-2095 Is elimination of hepatitis C across an entire prison network possible? A nurse-led test and treat model in 47 English prisons Andy Jones Received Received
  PO-2097 Impact of COVID-19 pandemic on referral of patients with liver disease to a liver transplant center Giacomo Germani Received Received
  PO-2098 GLAST redistributes, clusters and forms homomultimers at the membrane of astrocytes Joana Patrícia Ventura Pereira Received Received
  PO-2099 Development of a disease-mimicking model for NASH and liver fibrosis in a triple cell-type, spheroid-based liver-on-chip platform with microfluidics Geurt Stokman Received Received
  PO-2103 Changhua-Integrated Program to Stop Hepatitis C Infection (CHIPS-C) of Taiwan Tsung-Hui Hu Received Received
  PO-2105 Hepatitis B virus surface antigen expression determines hepatic immunity and Kupffer cell functions in HBV-transgenic mice Stefan Schefczyk Received Received
  PO-2106 T-cell engagers that bind HBV envelope proteins enable T cells to control the infection and to target hepatoma in mice Oliver Quitt Received Received
  PO-2108 The global NAFLD preparedness index: are countries ready to tackle the challenge? Jeffrey V Lazarus Received Received
  PO-2113 Proteomic profiling of hepatic stellate cell differentiation from induced pluripotent stem cells: new tools to understand liver development and fibrosis Raquel A. Martinez Garcia de la Torre Received Received
  PO-2120 Treatment with seladelpar in patients with primary biliary cholangitis (PBC) and prior experience with obeticholic acid (OCA) or fibrates Aliya Gulamhusein Received Received
  PO-2121 The impact of COVID-19 on liver transplant (LT) centers across the world during the first wave: a Multisociety Survey (EASL-ESOT/ELITA-ILTS) Francesco Paolo Russo Received Received
  PO-2122 Decreased Overall Mortality and Mortality without Liver Transplantation with N-Acetylcysteine in Non-acetaminophen-induced Acute Liver Failure: A Systematic Review and Meta-Analysis Adrian Alick Bonghanoy Received Received
  PO-2123 Liver Biopsy Graph Neural Networks for automated histologic scoring using the NASH CRN system Maryam Pouryahya Received Received
  PO-2127 The road to hepatitis C virus elimination: entering the final stretch or chasing a moving finish line? Sigurdur Olafsson Received Received
  PO-2131 A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission Alexander Stockdale Received Received
  PO-2134 The association of serum hepatitis B core antibody and liver inflammation in HBeAg-negative chronic hepatitis B patients with normal ALT and detectable HBV DNA Chao Wu Received Received
  PO-2135 A specific deletion pattern in the preS1- and preS2-domain is associated with treatment induced HBsAg loss in chronic hepatitis B Maria Pfefferkorn Received Received
  PO-2136 Clinical decompensation and outcomes in patients with biopsy proven cirrhosis and a hepatic venous pressure gradient = 10 mm Hg Ankur Jindal Received Received
  PO-2138 Safety and efficacy of direct acting antiviral therapy for chronic HCV infection in elderly people Daniela Maggi Received Received
  PO-2145 Conservation, variability and evolution of Hepatitis Delta virus in antigen coding region Beatriz Pacin Received Received
  PO-2147 Intestinal Epithelial Cell Death In Cirrhosis And Acute-on-Chronic Liver Failure Stijn den Daas Received Received
  PO-2152 Modelling Clinical Outcomes of NASH in the United States Stratified by Presence of Type 2 Diabetes Carey Escheik Received Received
  PO-2154 Characterization of in-vitro responses to different immune modulation of HBV core18-specific vs HBV pol455-specific CD8 T cells Elmira Aliabadi Received Received
  PO-2161 Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice Mohammad Kabbani Received Received
  PO-2162 Value of Hitachi Shear Wave Elastography (SWE) to rule-in and rule-out the presence of esophageal varices in patients with compensated advanced liver disease Simona Bota Received Received
  PO-2163 Inhibition of integrin alphaVbeta1 and alphaVbeta6 by a small molecule inhibitor attenuated liver fibrosis and tumor formation in an advanced mouse NASH model Dipankar Bhattacharya Received Received
  PO-2173 Treatment with GSK3228836 leads to HBsAg reduction and induction of interferon gamma related proteins and chemokines in a Phase 2a, randomized, double-blind, placebo-controlled study Shihyun You Received Received
  PO-2178 Low baseline cortisol but not delta cortisol relates to 28-day transplant-free survival in acute liver failure syndromes Sofia Roth Received Received
  PO-2181 Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review Fraquelli Mirella Received Received
  PO-2184 Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases André L. Simão Received Received
  PO-2185 Human Precision Cut Liver Slices as a model of Alcohol-related Liver Disease: recapitulating disease progression in a dish. Elena Palma Received Received
  PO-2186 Imaging by Desorption electrospray ionization mass spectrometry detects changes in lobular patterns of lipids in non-alcoholic fatty liver disease Patcharamon Seubnooch Received Received
  PO-2191 Directly observed therapy for hepatitis C alongside opioid agonist therapy as an effective microelimination strategy for PWIDs with a high risk for non-adherence in Vienna, Austria Michael Schwarz Received Received
  PO-2192 Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis MARINA SERRANO-MACIÁ Received Received
  PO-2193 Evaluation of hepatitis C virus (HCV) core antigen assay from venepuncture compared to HCV RNA in plasma: a cohort study from Pakistan. Saeed Hamid Received Received
  PO-2194 Multimodal assessment of neurocognitive impairment in a prospective cohort of patients with chronic liver disease:One third of patients do not have hepatic encephalopathy Philippe Sultanik Received Received
  PO-2203 Diagnostic role of liver biopsy in patients with acute liver failure or acute liver injury Peter Hunyady Received Received
  PO-2204 Modeling phenotypic heterogeneity of Glycogen Storage Disease type Ia liver disease in mice by somatic CRISPR/Cas9-mediated gene editing Martijn Rutten Received Received
  PO-2205 Delivering elimination: rapid scale-up of hepatitis c virus treatment among people who inject drugs in Tayside, Scotland Christopher Byrne Received Received
  PO-2210 A 3D in vitro screening-based discovery approach for ing and prioritizing NASH drug candidates Radina Kostadinova Received Received
  PO-2211 Long-term survival after living donor liver transplantation in primary sclerosing cholangitis Timur Liwinski Received Received
  PO-2218 Cost-effectiveness of a Core Antigen Based Rapid Diagnostic Test for Hepatitis C Madeline Adee Received Received
  PO-2223 Proposal and validation of a novel scoring system for hepatocellular carcinomas beyond curability borders: Unresectable hepatocellular carcinoma prognostic index Coskun Ozer Demirtas Received Received
  PO-2227 Diagnostic and prognostic value of miR-16, miR-146a and miR-192 in exosomes of hepatocellular and liver cirrhosis patients Thorben Frndt Received Received
  PO-2230 Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosis cholangitis: a multicentre, retrospective study Ida Schregel Received Received
  PO-2234 In vitro Transplantation of Biliary Organoids Support Hepatic Differentiation and proliferation in Chronic Liver Injury Impreet Kaur Received Received
  PO-2238 Influence of Shunt occlusion on Organ Functions in Hyperammonemic patients with Cirrhosis having Porto-systemic Shunt: a randomized controlled trial Amar Mukund Received Received
  PO-2240 Real-time utility of response-guided DAA therapy for hepatitis C based on a mathematical modeling approach:database formation and machine learning methods Harel Dahari Received Received
  PO-2242 Incidence of Hepatocellular carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A systematic Review, Meta-Analysis and Metaregression Marco Sanduzzi Zamparelli Received Received
  PO-2243 Control of APOBEC3B induction and transcription-independent Hepatitis B virus episome decay by NF-kB and miR-138-5p Suzanne Faure-Dupuy Received Received
  PO-2259 Intravenous ketamine and progressive cholangiopathy in covid-19 patients Kilian Bock Received Received
  PO-2261 Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single Italian reference center report Gabriele Ricco Received Received
  PO-2269 HBsAg, HBcrAg, and HBV RNA in outcomes and after NA discontinuation in HBeAg negative patients with chronic hepatits B: results from the Toronto STOP Study Arif Sarowar Received Received
  PO-2273 The impact of age in clinical outcomes in cirrhotic outpatients Marta Tonon Received Received
  PO-2275 Prevalence of resistance associated substitutions in hepatitis C virus NS5A against direct acting antivirals Zain Ul Abideen Received Received
  PO-2276 Ripk3 depletion improves mitochondrial bioenergetics and function in experimental NAFLD Tawhidul Islam Received Received
  PO-2279 Obese-induced brain sphingolipid dysregulation in bile-duct ligated rats accelerates and exacerbates hepatic encephalopathy Rafael Ochoa-Sanchez Received Received
  PO-2280 Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute on chronic liver failure Sanchit Sharma Received Received
  PO-2285 Vitamin B6 deficiency associates with liver transplantation-free survival in primary sclerosing cholangitis Peder Rusten Braadland Received Received
  PO-2287 Oral LPCN 1144 treatment significantly reduced liver fat and key liver injury markers in biopsy confirmed NASH subjects: Results of a Phase 2 randomized controlled study Kilyoung Kim Received Received
  PO-2290 Aminotransferase improvements in patients with non-alcoholic steatohepatitis are associated with fibrosis regression in the REGENERATE study Denise Frontin Received Received
  PO-2293 Low anti-HBc levels are associated with lower risk of virological relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative patients. Valerie Ohlendorf Received Received
  PO-2294 Prognostic impact of Hepatic venous pressure gradient cut-off of 10mm Hg to predict clinical decompensations in patients with compensated cirrhosis with liver stiffness above 25 kilopascals Sanchit Sharma Received Received
  PO-2295 Amino acid substitutions associated with treatment failure of hepatitis C virus infection Carlos García-Crespo Received Received
  PO-2297 BIO89-100 demonstrated robust reduction in liver fat fraction and liver fat volume (LFV) and favorable tolerability with weekly (QW) and every 2 weeks (Q2W) dosing in a Phase 1b/2a placebo-controlled proof of concept study in NASH Maya Margalit Received Received
  PO-2298 Prediction of cardiac outcomes post-transjugular intrahepatic portosystemic shunt placement using cirrhotic cardiomyopathy criteria Claire Harrington Received Received
  PO-2305 Rifaximin for Prophylaxis of Post-TIPPS Hepatic Encephalopathy- A Meta Analysis Aminah Abdul Razzack Received Received
  PO-2307 Ex vivo immune checkpoint blockade differentially regulates IFN-gamma and IL-2 responses in HBV-specific T cells across clinical HBV phases Conan Chua Received Received
  PO-2312 Novel liver-specific thyromimetic for the treatment of steatohepatitis Andrea Perra Received Received
  PO-2313 IL-1Ra, IL-18 and TREM-1 circulating factors and CDve HLADR-low TIM3ve suppressive monocytes predict development of sepsis within 3 days in patients with acute on chronic failure Pushpa Yadav Received Received
  PO-2319 Validation of non-invasive criteria for diagnosis of clinically significant portal hypertension in compensated advanced chronic liver disease of different etiologies in an asian cohort Sanchit Sharma Received Received
  PO-2320 Efficacy and Safety of Sofosbuvir\Ledipasvir Combination or Nitazoxanide in Treatment of COVID-19: A Placebo-Controlled, Randomized Clinical Trial Mohammed Medhat Received Received
  PO-2322 Exposure to environmental contaminants is associated with sex-specific disturbances of hepatic lipid metabolism in non-alcoholic fatty liver disease Matej Oresic Received Received
  PO-2324 Incidence and impact of PYLEPHEBITIS in PYOGENIC LIVER ABSCESS Nicolas Drilhon Received Received
  PO-2326 Assessment of how modifiable and non-modifiable factors can impact fibrosis outcomes in non-alcoholic steatohepatitis patients: a 12-country real-world assessment Victoria Higgins Received Received
  PO-2328 NAFLD and colorectal adenoma - rather an association than causality Georg Semmler Received Received
  PO-2329 High prevalence of low normal or overtly hypogonadal levels of testosterone observed in histologically established NASH subjects in LiFT Study Benjamin Bruno Received Received
  PO-2331 Past hospital contacts due to alcohol do not predict fibrosis stage in alcohol-related liver disease. A study of alcohol diagnoses and morbidity in 18 years leading up to biopsy-proven liver fibrosis in 462 patients Ditlev Nytoft Rasmussen Received Received
  PO-2338 Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy & safety results from a phase 2, open-label study Young Suk Lim Received Received
  PO-2339 Impact of hepatitis B core-related antigen (HBcrAg) level on HBV specific CD4 and CD8 T cell responses in HBeAg negative patients with chronic hepatitis B virus infection Elmira Aliabadi Received Received
  PO-2341 High oxidative stress in T cells and monocytes correlates with mortality from alcoholic hepatitis Huey Tan Received Received
  PO-2343 Does fibrosis severity or diabetes status influence patient-reported lifestyle changes and degree of success among non-alcoholic steatohepatitis patients? Victoria Higgins Received Received
  PO-2352 Beating Hepatitis C together in challenging times: an evaluation of a multi-disciplinary approach to testing and treating homeless people temporarily housed during the COVID-19 pandemic Tracey Stirrup Received Received
  PO-2358 Pulmonary impairment determines mortality in critically ill patients with acute-on-chronic liver failure Martin Schulz Received Received
  PO-2359 Hepatitis B and C screening in hospitalized SARS-CoV-2 patients Judith Gómez-Camarero Received Received
  PO-2363 Role of farensoid-X receptor agonist in ameliorating NASH-disrupted intestinal permeability: Potential impact of autophagy on tight junctions Rasha Tawfiq Received Received
  PO-2364 The added value of PIVKA-II levels over AFP in patients with hepatocellular carcinoma undergoing locoregional treatment massimo iavarone Received Received
  PO-2366 Nonalcoholic fatty liver disease in chronic hepatitis B patients: patients characterization and impact on disease progression Fadi Abu Baker Received Received
  PO-2369 Current non-invasive tests have suboptimal performance for the identification of candidates for pharmacological therapy for pre-cirrotic non-alcoholic steatohepatitis. Jesús Rivera Received Received
  PO-2370 Evaluation of the newly proposed criteria for clinically significant portal hypertension using platelets and transient elastography Kristian Podrug Received Received
  PO-2375 Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma Campani Claudia Received Received
  PO-2377 Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD) - A Secondary Analysis of Two Randomized Controlled Trials Angel Borisov Received Received
  PO-2382 Role of sex on the development of sarcopenia and ammonia metabolism in bile-duct ligated rats Mariana M. Oliveira Received Received
  PO-2386 Dynamic liver function tests and liver elastography in cardiac amyloidosis - preliminary data from AmyKoS Sandra Ihne Received Received
  PO-2387 Implementation of a coordinated hepatocellular carcinoma screening program in an outpatient liver center Joana Vieira Barbosa Received Received
  PO-2388 FXR Controls Effector Cytokine Production and Phenotype in Biliary Atresia Annika Yang vom Hofe Received Received
  PO-2389 Hospitalization Outcomes of Acute Alcoholic Hepatitis with Protein Energy Malnutrition - A nationwide Analysis Adnan Malik Received Received
  PO-2392 Liver Involvement is rare during COVID -19 Infection In Children cigdem Arikan Received Received
  PO-2395 Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy & safety results from a phase 2 study Harry Janssen Received Received
  PO-2401 Tailoring the management of HCC during the COVID-19 pandemic: a single center comparative analysis of 4 periods during 2020 versus 2019 massimo iavarone Received Received
  PO-2403 A single assessment of acute hemodynamic response to intravenous propranolol predicts hepatic decompensation in cirrhotic patients with portal hypertension Benedikt S Hofer Received Received
  PO-2408 The Number of Small Hepatocellular Carcinoma Nodules in Patients within the Alpha-Fetoprotein Score before Liver Transplantation Is a Prognostic Risk Factor Alina Pascale Received Received
  PO-2411 Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of nonalcoholic fatty liver disease Giulia Lori Received Received
  PO-2412 Combining non-selective beta blockers with farnesoid X receptor agonists towards ameliorating intestinal barrier dysfunction in non-alcoholic steatohepatitis Yasmeen Attia Received Received
  PO-2415 An integrated approach on immune cell subtype characterization reveals common inflammatory pathways in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) Milessa Afonso Received Received
  PO-2420 Impact of a loss-of-function variant in HSD17B13 on hepatic decompensation and mortality in cirrhotic patients Antonio Gil-Gomez Received Received
  PO-2422 Safety, efficacy, & pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study Young-Suk Lim Received Received
  PO-2424 An interactive, country specific, online tool to assess the cost-effectiveness of different hepatitis C testing pathways to inform hepatitis C elimination Madeline Adee Received Received
  PO-2429 Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis b Harry Janssen Received Received
  PO-2456 Transient Kupffer cell response to microbial components is critically regulated through expression of A20 Christian Zwicker Received Received
  PO-2474 Novel HBV cure strategy: Leveraging HBV pol for infected cell-specific killing - In vivo proof-of-concept Serhat Gumrukcu Received Received
  PO-2476 Development and multicenter external validation of FIB-6; a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with chronic hepatitis C Gamal Shiha Received Received
  PO-2483 The impact of universal hepatitis B vaccine on the trend of hepatitis B virus attributable liver cancer from Global Burden of Disease Study 2017 Wen-Qiang He Received Received
  PO-2484 Nomogram for predicting significant liver injury in chronic hepatitis B patients with immune tolerance Dong Ji Received Received
  PO-2524 Quality of life improvement is a top-rated but rarely assessed outcome in European and Australian patients with hepatic encephalopathy: Quality of life targeting and monitoring needs to be prioritised Juha Halonen Received Received
  PO-2529 Effects and safety of atrial natriuretic peptide administered to cirrhosis patients with ascites: a systematic review and meta-analysis Rasmus Hvidbjerg Gantzel Received Received
  PO-2531 Fluid dynamics analyses of the portal vein flow changes after hepatectomy using 7T 3D PC-MRI Yu OSHIMA Received Received
  PO-2547 CLIF-SOFA accurately predicts in-hospital mortality in patients with cirrhosis and bacterial infection Minjong Lee Received Received
  PO-2572 Achieving an effective pressure reduction after TIPS for cirrhotic patients with variceal bleeding Xiaoze Wang Received Received
  PO-2575 Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study Qing Zhu Received Received
  LBP-2580 ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH Edward Gane Received Received
  PO-2583 Indirect healthcare costs in biopsy-proven NAFLD is higher than in matched controls and independent of comorbidities Hannes Hagstrm Received Received
  PO-2586 Uptake of Direct Acting Antivirals for treatment of hepatitis C in human immunodeficiency virus/ hepatits C co-infected children and adolescents in the Russian Federation Farihah Malik Received Received
  PO-2594 Free Androgen Index Levels May Influence the Transarterial Chemoembolization with Doxorrubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results. Silvia Acosta-López Received Received
  PO-2596 Hepatitis C Virus Microelimination is Feasible During COVID-19 Pandemic in Centers for Addiction Treatment Users Silvia Acosta-Lopez Received Received
  PO-2601 TIGITTIM-3NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma Lihua Yu Received Received
  PO-2609 Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: international registry data Thomas Marjot Received Received
  PO-2612 Prior or current hepatocelllular carcinoma does not adversely affect the evolution of LI-RADS 4 lesions. Louise Hanly Received Received
  PO-2619 Effects of tenofovir alafenamide fumarate treatment in pregnant women on maternal viral load reduction and preventing mother-to-infant HBV transmission Huey-Ling Chen Received Received
  PO-2621 Fixed 8-mm diameter VCX stents do not provide clinical advantages compared to former underdilated VTS stents in cirrhotic patients treated with TIPS for refractory ascites Sohab Mansour Received Received
  PO-2623 Myeloid-specific fatty acid transport protein 4 deficiency in mice induces a shift towards M2 macrophages that leads to aggravation of NASH after high-fat/high-cholesterol feeding Deniz Gcebe Received Received
  PO-2627 Hepatocytes Caspase6 inhibition exacerbated inflammation and fibrosis in 3D liver spheroids, stellate cells, and the GAN mouse model of NASH Hani Jouihan Received Received
  PO-2628 Novel Copper Protein Speciation method for calculating Serum Non Ceruloplasmin Copper: A comparative analysis Tim Morley Received Received
  PO-2634 Real-world use of avatrombopag in patients with severe thrombocytopenia associated with chronic liver disease undergoing a procedure Beverley Wilson Received Received
  PO-2637 In HBeAg-negative patients within grey zone, serum HBV-RNA levels are higher and more commonly detected, while intrahepatic markers are similar Adriana Palom Received Received
  PO-2653 Blocking the CD47-SIRPa axis in nonalcoholic steatohepatitis enhances necroptotic hepatocyte uptake and improves hepatic fibrosis Hongxue Shi Received Received
  PO-2657 Patient perspectives on pruritus in intrahepatic cholestasis of pregnancy: a multinational survey Elaine Chien Received Received
  PO-2667 Three-fold increased risk for death in Budd-Chiari syndrome compared to matched controls - population-based cohort study Hannes Hagstrm Received Received
  PO-2673 Colonic permeability is increased in non-cirrhotic nonalcoholic fatty liver disease Toon De Munck Received Received
  PO-2681 Altered DNA methylation characterizes autoimmune hepatitis Kalliopi Zachou Received Received
  PO-2683 Validation of a novel point-of-care test for gut leakage in cirrhosis based on dimeric to monomeric IgA ratio: a pilot cohort study Jessica Howell Received Received
  PO-2685 Using dimeric to monomeric IgA ratio to diagnose portal hypertension in liver disease: a pilot cohort study Jessica Howell Received Received
  PO-2687 SARS-CoV-2 one year on - the worrying impact on early detection of primary liver cancers Daniel Geh Received Received
  PO-2688 Safety and immunogenicity of Coronavirus disease 2019 vaccination in patients with chronic liver disease: a multicenter study xiaolong qi Received Received
  PO-2689 Proportion, characteristics, and outcome of chronic hepatitis B who are linked to care in Korea: A nationwide retrospective longitudinal study Eileen Yoon Received Received
  PO-2695 FIB-4 based algorithm for screening significant fibrosis in diabetes with or without fatty liver in primary care setting Eileen Yoon Received Received
  PO-2697 Defining the range of healthy volunteer non ceruloplasmin copper using a new Copper Protein Speciation assay Tim Morley Received Received
  PO-2701 Artificial Intelligence and Digital Single-Operator Cholangioscopy: automatic identification of tumor vessels in patients with indeterminate biliary strictures. Miguel Mascarenhas Received Received
  PO-2704 The Alcohol-Associated Liver Disease Paradox in Chile: An Assessment with data from the National Health Survey 2016-2017. Juan Pablo Roblero Received Received
  PO-2708 Impact of direct-acting antiviral treatment on mortality related to extrahepatic manifestations: findings from a large population-based cohort in British Columbia, Canada Dahn Jeong Received Received
  PO-2710 Gamma-Glutamyl Transpeptidase Dynamics as a Biomarker for Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease Yeonjung Ha Received Received
  PO-2712 Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma Yeonjung Ha Received Received
  PO-2719 Cholangiopathy associated with checkpoint inhibitors: a case series Philip Berry Received Received
  PO-2724 Budesonide versus prednisolone in the treatment of autoimmune hepatitis: a cross-sectional patients survey Ceyhun Aksel Oztumer Received Received
  LBP-2730 Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study Maria Gil Received Received
  PO-2732 Core liver homeostatic networks: implications in therapeutic target discovery, pre-clinical studies, and innovative trial designs Saeed Esmaili Received Received
  PO-2735 Durability of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens Juanjuan Shi Received Received
  PO-2738 Functional cure based on pegylated interferon a in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: A multicenter real-world study(everest project in china), a sequential report the predictors for HBsAg loss Ze-Qian Wu Received Received
  PO-2739 In type-2 diabetic patients, the identification of at-risk NASH is impacted by age: a comparison of serum-based NITs including NIS4 Axelle Louard Received Received
  PO-2742 Preoperative artemin as predictive biomarker for survival in curatively resected hepatocellular carcinoma Ulf Zeuge Received Received
  PO-2749 The combination of ABICELF as a single marker outperforms ABIC alone in predicting 90-day survival in alcoholic hepatitis. Freya Rhodes Received Received
  PO-2753 Supplementation of branched-chain amino acids improves event-free survival in cirrhotic patients: systematic review and meta-analysis Karel J. Van Erpecum Received Received
  PO-2755 A lesson from COVID19: the persevering benefits of hepatocellular carcinoma surveillance William Cunliffe Received Received
  PO-2759 Short-term peginterferon alpha re-treatment induced a high functional cure rate in patients with hepatitis B surface antigen recurrence after cessation of peginterferon alpha-based regimens Juanjuan Shi Received Received
  PO-2761 Ischemic cholangiopathy in biliary atresia: immunohistochemical and molecular evidence Jorge Luiz santos Received Received
  PO-2770 Optimization of CRISPR/Cas9 technology for a safer treatment of rare metabolic disorders Laura Torella Received Received
  PO-2786 Insulin like growth factor-1 as a prognostic tool for overall survival in chronic hepatitis C cirrhotic Egyptian patients with hepatocellular carcinoma Ahmed Sultan Received Received
  PO-2787 Identifying effective subtype-specific treatment responses in hepatocellular carcinoma in genetically engineered mouse models Miryam Mller Received Received
  PO-2788 Umbilical hernia repair in Cirrhosis: TIPS insertion improves one-year survival but not long-term outcomes Abdullah Malik Received Received
  PO-2790 Liver fibrosis accumulation depends on underlying disease aetiology Adam Watson Received Received
  PO-2791 Liver test-derived R factor is associated with portal hypertension in patients with non-alcoholic fatty liver disease Dor Shirin Received Received
  PO-2793 Disrupted glucose-6-phosphate-ChREBP signalling aggravates hepatomegaly and accelerates liver disease progression in a mouse model for Glycogen Storage Disease type 1a Martijn Rutten Received Received
  PO-2798 Phosphoinositide 3-kinase dependent carcinogenesis in the liver Dayana Tsolova Received Received
  PO-2799 Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters. Sergio Muñoz-Martínez Received Received
  PO-2801 Artificial Intelligence for automatic diagnosis of biliary strictures malignancy status in Single-Operator Cholangioscopy. Miguel Mascarenhas Received Received
  PO-2812 Trend and correlates of increased serum alpha-fetoprotein in hepatocellular carcinoma: US National Cancer Database analysis Aarshi Vipani Received Received
  LBP-2814 Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress Sarah Blach Received Received
  PO-2821 SARS-CoV-2-specific cellular and humoral immunity in COVID-19 convalescence after liver transplantation Theresa Kirchner Received Received
  PO-2822 Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA Emily Thi Received Received
  PO-2823 Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers Emily Thi Received Received
  PO-2828 Characterization of disease progression and pharmacological intervention in the GAN diet-induced obese mouse model of NASH with advanced fibrosis and hepatocellular carcinoma Michael Feigh Received Received
  PO-2830 A novel histological scoring system for primary sclerosing cholangitis: Impact on disease outcome Nelli Sjblom Received Received
  PO-2832 High prevalence of hormonal changes and hepatic osteodystrophy in Frail patients with cirrhosis An observational study Surender Singh Received Received
  PO-2833 Early and late changes in the phenotype of liver sinusoidal endothelial cells (LSECs) along the development of heart failure Kamila Wojnar-Lason Received Received
  PO-2834 HBsAg protein composition differs across stages of hepatitia B and hepatitis Delta: a validation cohort study Luisa Roade Received Received
  PO-2836 Higher all-cause mortality in individuals living with HIV cured of HCV by direct-acting antivirals compared to HIV mono-infection despite controlled HIV: Results from the ANRS-CO4 FHDH cohort Maria Requena Received Received
  PO-2839 A new mouse model of intrahepatic cholangiocarcinoma uncovers a role for TNS4 in tumor progression Sophie Pirenne Received Received
  PO-2842 Periods of high or low intensity transplant activity are not associated with changes in liver transplant outcomes Neil Halliday Received Received
  PO-2844 A phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results Pietro Scalfaro Received Received
  PO-2851 In vitro skeletal muscle cell atrophy and mitochondrial dysfunction after exposure to human serum from patients with ESLD and NAFLD Sophie Allen Received Received
  PO-2853 The incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis during long-term antiviral therapy: A real world cohort study Ying Han Received Received
  PO-2858 Role of the nuclear receptor Farnesoid X Receptor in the immune functions of the intestine in the pathophysiological context of Non Alcoholic SteatoHepatitis Margaux Nawrot Received Received
  PO-2861 Projecting the prevalence of obesity- and alcohol- related non-communicable diseases in France, the Netherlands and Romania from 2020 to 2030 using multi-risk microsimulation methods Lise RETAT Received Received
  PO-2865 Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches Anne-Aurélie RAYMOND Received Received
  PO-2867 Hepatogenous diabetes in patients with cirrhosis and ascites: correlation with inflammatory activity, systemic hemodynamics, renal function, and outcome Ilias Tsiakas Received Received
  PO-2870 Methylation state of circulating cell-free DNA as a prognostic marker for early to late stage chronic liver disease and acute on chronic liver failure Aikaterini Tourna Received Received
  PO-2872 COVID - 19 pandemic and the impact on hospitalization of alcohol related liver disease - A retrospective cohort study in a secondary care setting Wei Jin Lim Received Received
  PO-2879 A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection Edward Gane Received Received
  PO-2883 The intestinal barrier is modified in mice suffering from non-alcoholic steatohepatitis Simon Peschard Received Received
  LBP-2886 LPCN 1144 improves body composition in biopsy-confirmed NASH patients Shadi Mehraban Received Received
  PO-2887 Artificial intelligence and digital single-operator cholangioscopy: automatic identification of neoplastic biliary nodules in patients with indeterminate biliary stenosis. Joao Afonso Received Received
  PO-2888 New insights in CCl4 induced acute liver injury in the presence and absence of Ripk1. Huma Hameed Received Received
  PO-2890 A new tool for predicting survival in liver transplantation for hepatocellular carcinoma combining molecular and clinical variables Joana Cardoso Received Received
  LBP-2891 Artificial intelligence and digital single-operator cholangioscopy: automatic identification of papillary projections in patients with indeterminate biliary strictures Tiago Ribeiro Received Received
  PO-2893 Micro ribonucleic acid- 26a as a diagnostic biomarker for hepatitis C induced hepatocellular carcinoma in Egyptian patients. Ahmed Sultan Received Received
  PO-2898 Artificial intelligence and digital single-operator cholangioscopy: automatic identification of neoplastic masses in patients with indeterminate biliary strictures Tiago RIbeiro Received Received
  PO-2902 Impact of SarsCov2 pandemic on vascular liver diseases Anna Baiges Received Received
  PO-2904 Impact of Universal Automated Hepatitis C Screening with Treatment and Cure in a Primary Care Based Practice Ruth Brogden Received Received
  LBP-2907 Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial Stephen Rossi Received Received
  PO-2910 Liver and/or kidney transplantation after SARS-CoV-2 infection: Prevalence, short-term outcome and kinetics of serum IgG antibodies Casper Vrij Received Received
  PO-2914 Fecal microbiota transplantation (FMT) for corticosteroids (CS) non-responders and non-eligible (NoReNE) patients with severe alcoholic hepatitis (SAH). Natália Bystrianska Received Received
  PO-2919 Transcriptomic analysis reveals circWHSC1 and circCPSF6 serves as the oncogene to promote hepatocelluar carcinoma progression Fei Lu Received Received
  PO-2936 Improving the Accuracy of Non-Invasive Tests for Prediction of Cirrhosis in Chronic Hepatitis Delta: Insights from 230 Patients of the D-LIVR Study Tarik Asselah Received Received
  PO-2938 Application of surrogate endpoints in compensated cirrhotic patients with primary biliary cholangitis Carla Fiorella Murillo Perez Received Received
  PO-2946 Patients with cirrhosis show an improvement in dynamic liver function following the eradication of hepatitis C virus with direct acting antivirals Ali Jibran Mecci Received Received
  PO-2951 An educational intervention that effectively reduces the inappropriate administration of proton pump inhibitors in patients with cirrhosis Juvelyn Palomique Received Received
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 23/06/2021 TO 23/06/2022
Featured Poster
Vote poster
Poster Discussion

Logo Draft
Logo Cert